Novel targeting compound and nucleic acid conjugate, and application thereof
By combining novel targeted compounds and nucleic acid conjugates with hepatocyte membrane receptors, the problem of low targeted delivery efficiency and high toxicity of RNAi agents in vivo in liver is solved, and efficient and stable regulation of hepatocyte gene expression and HBV inhibition effect is achieved. .
Patent Information
- Application Number
- CN202410566137.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively deliver RNAi agents to the liver, especially in the extracellular environment in the body (especially serum protein), and there are problems of low delivery efficiency and high toxicity.
A novel targeting compound and nucleic acid conjugate has been developed to form nucleic acid conjugates by conjugating to oligonucleotides, using specific conjugation groups (such as oligonucleotide conjugates containing GalNAc) and The binding of hepatocyte membrane receptors achieves gene expression regulation in hepatocytes, improves delivery efficiency and stability, and reduces toxicity.
Oligonucleotide drugs delivered to liver cells are achieved efficiently, which significantly improves gene expression inhibitory activity and reduces the toxicity of the drug, especially in the inhibition of HBV gene expression.
Smart Images

Figure BDA0004829315530000021 
Figure BDA0004829315530000022 
Figure BDA0004829315530000061
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of drug delivery. The purpose of the present invention is to provide a novel targeting compound and a nucleic acid conjugate and uses thereof. The present invention also relates to a novel conjugate group, which is used for the delivery of small nucleic acid drugs (such as siRNA, ASO, etc.), and can be conjugated with nucleotides to form a nucleic acid conjugate. The nucleotide conjugate is used to regulate gene expression in hepatocytes to prevent and / or treat related diseases. Background Art
[0002] RNA interference (RNAi) is a phenomenon in which double-stranded RNA (dsRNA) molecules shut down the expression of homologous genes or silence the expression of the gene at the mRNA level. RNA interference technology is also vividly called gene knock-down or gene silencing. It is a typical post-transcriptional gene regulation method, also known as post-transcriptional gene silencing (PTGS). The earliest report on RNA interference appeared in 1990, when two different research groups simultaneously reported the RNA interference phenomenon in transgenic plants. Later, RNA interference was observed in almost all eukaryotic organisms such as nematodes, fruit flies, zebrafish and mice. In 1999, Hamilton and Baulcombe detected RNA fragments with a length of 21-25 nucleotides in plants with RNA interference. These RNA fragments were proved to be necessary for RNA interference and were called small interfering nucleic acids (siRNA). Double-stranded siRNA forms an RNA-induced silencing complex (RISC) with cell-derived related enzymes and proteins. During RNA interference, the sense strand in the double-stranded siRNA is excluded from the complex, and the antisense strand guides RISC to bind to the homologous site of the target mRNA. The target mRNA is then degraded by ribonuclease III in the complex, thereby shutting down the expression of the target gene.
[0003] The effective delivery of RNAi agents to cells in vivo requires specific targeting and substantial protection against the extracellular environment (particularly serum proteins). One method to achieve specific targeting is to conjugate (also called conjugation) a targeting moiety to the RNAi agent. The targeting moiety helps target the RNAi agent to the desired target site. One way in which the targeting moiety can improve delivery is through receptor-mediated endocytosis activity. The mechanism of this uptake includes the internal movement of the RNAi agent bound to a membrane receptor to a region, through the invagination of the membrane structure or through the fusion of the delivery system with the cell membrane, and the membrane surrounds the region. This process is initiated by the activation of the cell surface or membrane receptor after a specific ligand is bound to the receptor.
[0004] In recent years, the use of N-acetylgalactosamine (GalNAc), a high affinity ligand of asialoglycoprotein receptor (ASGPR), as a targeting molecule has achieved good results in liver-targeted delivery of nucleic acid drugs. Patent application WO2009073809A2 discloses an oligonucleotide conjugate containing three clusters of N-acetylgalactosamine (GalNAc), wherein the fragment containing GalNAc is connected to the oligonucleotide via 3-hydroxy-5-hydroxymethylpyrrolidine, and these conjugates have the activity of inhibiting the expression of corresponding genes in cells. Summary of the invention
[0005] The present invention provides a new targeting compound, which can be used to prepare a nucleic acid conjugate drug for targeted delivery of oligonucleotides to the liver. The present invention also provides a new targeting conjugate group (i.e., a carrier) that can effectively deliver oligonucleotides to liver cells. The present invention also provides a nucleotide conjugate, a preparation method and an application thereof, which has a higher in vivo delivery efficiency, better stability, higher gene expression inhibition activity in hepatocytes and / or lower toxicity. On the other hand, the present invention further provides a siRNA reagent, a preparation method and an application thereof, which has a higher in vivo delivery efficiency, better stability, higher gene expression inhibition activity and / or lower toxicity to HBV.
[0006] In one aspect, the present invention relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),
[0007]
[0008] Wherein, Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms;
[0009] Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(═O)(CH 2 ) j C(=O)- or MC(=O)(CH 2 ) j C(=O)-;
[0010] M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG;
[0011] Each L 1 , L 2 and L 3 Independently for C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-;
[0012] R is a structure represented by the following formula (a) or formula (b):
[0013]
[0014] Among them, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H or a hydroxyl protecting group; each Y 1 , Y 2 , Y 3 , Y 4 , Y 5 are independently H or an amino protecting group;
[0015] Each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5Independently for the key, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-;
[0016] Each B 1 , B 2 , B 3 , B 4 and B 5 Independently for C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein B 1 and B 2 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3 to 12 ring atoms, B 3, B 4 and B 5 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, wherein each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-;
[0017] Each R 1 are independently H, deuterium or C 1-6 alkyl;
[0018] wherein each j is independently 1, 2, 3, 4 or 5;
[0019] Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
[0020] In some embodiments of the compounds of the present invention, each L 1 , L 2 and L 3 Independently for C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-12 Alkyl, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1)-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0021] In some embodiments of the compounds of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0022] In some embodiments of the compounds of the present invention, each B 1 , B 2 , B 3 , B 4 and B 5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein B 1 and B 2 At least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3 to 6 ring atoms, B 3 , B 4 and B 5 At least one of them is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W3 Has the meaning described in the present invention.
[0023] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(═O)(CH 2 ) j C(=O)- or MC(=O)(CH 2 ) j C(=O)-, wherein the hydroxyl protecting group is an ester protecting group, an alkoxyalkyl protecting group, a silyl protecting group, a substituted or unsubstituted aryl protecting group, a substituted or unsubstituted arylalkyl protecting group (such as triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, etc.), wherein each M and j has the meaning described in the present invention.
[0024] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkyl methyl, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described in the present invention;
[0025] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0026] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkyl methyl, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described in the present invention;
[0027] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0028] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkyl methyl, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described in the present invention;
[0029] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0030] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkyl methyl, C1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(=O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, wherein each M and j have the meanings described in the present invention;
[0031] The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0032] In some embodiments of the compounds of the present invention, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-;
[0033] Each Y 1 , Y 2 , Y 3 , Y 4 and Y 5 are independently H, 9-fluorenylmethoxycarbonyl or R3 C(=O)-;
[0034] Among them, each R 2 and R 3 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl;
[0035] Each R 1 are independently H, deuterium or C 1-4 alkyl;
[0036] Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0037] In some embodiments of the compounds of the present invention, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C1-6 Alkoxy or R 2 C(=O)-;
[0038] Each Y 1 , Y 2 , Y 3 , Y 4 and Y 5 are independently H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-;
[0039] Among them, each R 2 and R 3 Independently for C 1-4 Alkyl, halogenated C 1-6 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl;
[0040] Each R 1 are independently H, deuterium or C 1-4 alkyl;
[0041] Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0042] In some embodiments of the compounds of the present invention, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 and X 15is H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-;
[0043] Each Y 1 , Y 2 , Y 3 , Y 4 , Y 5 is H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-;
[0044] Among them, each R 2 and R 3 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl;
[0045] Each R 1 are independently H, deuterium or C 1-4 alkyl;
[0046] Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 1-4 Alkenyl or C 1-4 Heteroalkyl.
[0047] In some embodiments of the compounds of the present invention, R is a structure represented by the following formula (a-1) or formula (b-1):
[0048] Among them, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , A 1 , A 2 , A 3 , A 4 , A 5 , B 1 , B 2 , B 3 , B 4 , B 5 , C 1 , C 2 , C 3 , C 4 and C 5 Has the meaning described in the present invention.
[0049] In some embodiments, the compound of the present invention has a structure as shown in formula (II), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II).
[0050]
[0051] Among them, each Z, Y, L 1 , L 2 , L 3 and R have the meanings as defined in the present invention.
[0052] In some embodiments, the compound of the present invention has a structure as shown in formula (III), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (III).
[0053]
[0054] Formula (III) wherein each D 1 , D2 and D 3 are independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH 2 - * or -N(R 1 )C(=O)CH 2 - * ;
[0055] Each F 1 、F 2 and F 3 are independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl;
[0056] Each n 1 、n 2 、n 3 、m 1 、m 2 、m 3 and m 4 are independently 0, 1, 2, 3 or 4,
[0057] Among them, each R 1 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , Y 3 , Y 4 , Y 5 , Z and Y have the meanings described in the present invention.
[0058] On the other hand, the present invention relates to a conjugated group comprising a structure as shown in formula (Ia), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (Ia),
[0059]
[0060] Among them, R x It is a structure of formula (c) or formula (d):
[0061]
[0062] Wherein, Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms;
[0063] Each L 1 , L 2 and L 3 Independently for C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-;
[0064] Each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1)-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-;
[0065] Each B 1 , B 2 , B 3 , B 4 and B 5 Independently for C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein B 1 and B 2 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3 to 12 ring atoms, B 3 , B 4 and B 5 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, wherein each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-;
[0066] Each R 1 are independently H, deuterium or C 1-6 alkyl;
[0067] Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
[0068] In some embodiments of the conjugated group of the present invention, each L 1 , L 2 and L 3 Independently for C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0069] In some embodiments of the conjugate group of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0070] In some embodiments of the conjugated group of the present invention, each B 1 , B 2 , B 3 , B 4 and B 5 are independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein B 1 and B 2 At least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3 to 6 ring atoms, B 3 , B 4 and B 5 At least one of them is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 RW3 Replace, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W3 Has the meaning described in the present invention.
[0071] In some embodiments of the conjugated group of the present invention, the ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably a cyclopentyl, pyrrolyl, furanyl or piperidinyl group.
[0072] In some embodiments of the conjugated groups of the present invention, the ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl. In some embodiments of the conjugated groups of the present invention, each R 1 are independently H, deuterium or C 1-4 alkyl;
[0073] Each R w1 , R w2 and R W3are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0074] In some embodiments of the conjugated group of the present invention, R x It is a structure shown in the following formula (c-1) or formula (d-1):
[0075] Among them, each A 1 , A 2 , A 3 , A 4 , A 5 , B 1 , B 2 , B 3 , B 4、 B 5 , C 1 , C 2 , C 3 , C 4 , C 5 , Y 1 , Y 2 , Y 3 , Y 4 and Y 5 The definitions of have the meanings set forth in the present invention.
[0076] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a),
[0077] Among them, each R x , L 1 , L 2 and L 3 The definitions of have the meanings set forth in the present invention.
[0078] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (III-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (III-a),
[0079]
[0080] Among them, each D 1, D 2 and D 3 are independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH 2 - * or -N(R 1 )C(=O)CH 2 - * ;
[0081] Each F 1 、F 2 and F 3 are independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl;
[0082] Each n 1 、n 2 、n 3 、m 1 、m 2 、m 3 and m 4 independently 0, 1, 2, 3 or 4;
[0083] Among them, each R 1 , Y 3 , Y 4 and Y 5 The definitions of have the meanings set forth in the present invention.
[0084] In another aspect, the present invention relates to a nucleic acid conjugate, which comprises the conjugation group of the present invention and a nucleic acid, wherein the nucleic acid is a modified or unmodified nucleic acid.
[0085] In some embodiments of the nucleic acid conjugates of the present invention, the nucleic acid is linked to the conjugated group via a phosphate group, a thiophosphate group or a phosphate group.
[0086] In some embodiments of the nucleic acid conjugate of the present invention, the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid, preferably siRNA; optionally, the conjugated group is preferably conjugated to the 3' end or 5' end of the sense strand of the siRNA, and more preferably to the 3' end of the sense strand of the siRNA.
[0087] In some embodiments of the nucleic acid conjugates of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the nucleic acid.
[0088] In another aspect, the present invention also relates to a siRNA nucleic acid conjugate, which is one of DAW30223, DAW30062, DAW30219, DAW30221, DAW30222 and DAW30255,
[0089] DAW30223:
[0090] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40002-4 (SEQ ID NO: 2)
[0091] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0092] DAW30062:
[0093] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40003-4 (SEQ ID NO: 3)
[0094] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0095] DAW30219:
[0096] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40004-4 (SEQ ID NO: 4)
[0097] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0098] DAW30221:
[0099] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40005-4 (SEQ ID NO: 5)
[0100] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0101] DAW30222:
[0102] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40007-4 (SEQ ID NO: 6)
[0103] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0104] DAW30255:
[0105] Sense strand (5'-3'): gs-us-cauc-Cf-a-Cf-Af-Af-ugagaguaca-DAW40007-4 (SEQ ID NO: 8)
[0106] Antisense strand (5'-3'): us-Gfs-uac-(Tgn)-cucauug-Uf-g-Gf-auga-cs-gs-a (SEQ ID NO: 9)
[0107] Among them, the conjugate groups DAW40002-4, DAW40003-4, DAW40004-4, DAW40005-4 and DAW40007-4 are each conjugated to the 3' end of the siRNA sense strand through a phosphate group, and the structures thereof are shown below respectively:
[0108]
[0109]
[0110] In another aspect, the present invention relates to a pharmaceutical composition comprising the siRNA conjugate of the present invention and a pharmaceutically acceptable carrier.
[0111] On the other hand, the present invention also relates to the use of the compound, the conjugated group or the nucleic acid conjugate of the present invention in the preparation of a drug for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in a liver cell.
[0112] In some embodiments, the present invention also relates to the use of the compound and the conjugated group described in the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0113] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of small nucleic acid drugs in vivo.
[0114] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of siRNA drugs or ASO drugs in vivo.
[0115] In some embodiments, the present invention also relates to the use of the nucleic acid conjugates of the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes. In some embodiments of the present invention, the nucleic acid (or small nucleic acid) of the present invention refers to siRNA or ASO.
[0116] In some embodiments of the use of the present invention, the specific gene is selected from, but not limited to: ApoB, ApoC3 (apolipoprotein C-III encoded by the human apolipoprotein C-III gene), AGT (angiotensinogen), ANGPTL3 (angiopoietin-like 3), PCSK9, LPA (lipoprotein (a)), SCD1, FVII, p53, HBV (hepatitis B virus) or HCV (hepatitis C virus).
[0117] On the other hand. The present invention also relates to the use of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222 described in the present invention and a composition comprising DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222 described in the present invention and a pharmaceutically acceptable carrier in the preparation of a medicament for treating and / or preventing hepatitis B. On the other hand, the present invention also relates to the use of DAW30255 described in the present invention or a composition thereof in the preparation of a medicament for treating and / or preventing hypertension.
[0118] Detailed description of the invention
[0119] Definitions and general terms
[0120] In the present invention, the terms "comprise" or "include" are open expressions, that is, including the contents specified in the present invention, but not excluding other contents.
[0121] In the present invention, the term "small interfering RNA (siRNA)" is a double-stranded RNA of 17 to 30 nucleotides in length, comprising a sense strand and an antisense strand. siRNA mediates the targeted cleavage of RNA transcripts in the RISC pathway by forming a silencing complex (RISC). Specifically, siRNA guides the specific degradation of mRNA sequences through the known RNA interference (RNAi) process, inhibiting the translation of mRNA into amino acids and proteins. For example, siRNA can regulate (e.g., inhibit) the expression of hepatitis B virus in cells.
[0122] In the present invention, the term "antisense strand (or guide strand)" includes a region that is substantially complementary to a target sequence, such as the mRNA of hepatitis B virus. "Sense strand (or follower strand)" refers to an iRNA strand that is substantially complementary to the antisense strand. The term "substantially complementary" refers to complete complementarity or at least partial complementarity, for example, the antisense strand is completely complementary to the target sequence or at least partially complementary. In the case of partial complementarity, mismatches can exist in the interior or terminal regions of the molecule, wherein the most tolerated mismatches exist in the terminal regions, for example, within 5, 4, 3 or 2 nucleotides at the 5'- and / or 3'-end of the iRNA.
[0123] It should be noted that "at least part of the antisense strand is substantially complementary to the mRNA" means that the antisense strand has a polynucleotide that is substantially complementary to a continuous portion of the mRNA of interest (e.g., the mRNA encoding the hepatitis B virus). Alternatively, if a polynucleotide is substantially non-interruptedly complementary to a portion of the mRNA encoding the hepatitis B virus, the antisense strand is complementary to at least a portion of the mRNA of the hepatitis B virus.
[0124] In the present invention, the term "target sequence" refers to a continuous portion of the nucleotide sequence of an mRNA molecule formed during transcription of a gene encoding hepatitis B virus, including mRNA that is an RNA processing product of a primary transcription product.
[0125] In the present invention, the term "inhibiting the expression of hepatitis B virus genes" includes any level of inhibition of hepatitis B virus (abbreviated as HBV) genes, for example, at least partial inhibition of hepatitis B virus gene expression, such as inhibition of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%. Wherein, the expression of hepatitis B virus genes can be evaluated based on the level of any variable related to the expression of hepatitis B virus genes, for example, the mRNA level of hepatitis B virus or the level of hepatitis B virus protein. Inhibition can be evaluated by a reduction in the absolute or relative level of one or more of these variables compared to a control level. A control level can be any type of control level utilized in the art, e.g., a baseline level before administration, or a level measured from a similar subject, cell or sample that has never been treated or treated with a control (e.g., a control with only a buffer or a control without an active agent).
[0126] In the present invention, "pharmaceutical composition" may refer to a composition used for the treatment of a disease, and may also be used for in vitro cell culture experiments. When used for the treatment of a disease, the term "pharmaceutical composition" generally refers to a unit dosage form, and may be prepared by any of the methods well known in the pharmaceutical field. All methods include the step of combining the active ingredient with an excipient that constitutes one or more accessory ingredients. Typically, the composition is prepared by uniformly and fully combining the active siRNA with a liquid excipient, a finely divided solid excipient, or both.
[0127] In the present invention, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, the "pharmaceutically acceptable" of the present invention refers to those approved by federal regulatory agencies or national governments or listed in the United States Pharmacopoeia or other generally recognized pharmacopeias for use in animals, especially humans.
[0128] In the present invention, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for a specific target dosage form. In addition to any conventional excipients incompatible with the RNAi (such as siRNA) of the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present invention.
[0129] In addition to any conventional excipients, to the extent that they are incompatible with the RNAi (such as siRNA) of the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a deleterious manner, their use is also contemplated by the present invention.
[0130] As used herein, the term "treatment" refers to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the development of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug, RNAi agent or siRNA to an individual to treat, cure, alleviate, improve, reduce or inhibit an individual's disease, including but not limited to administering a drug containing an RNAi agent, siRNA or siRNA conjugate described herein to an individual in need.
[0131] Unless otherwise specified, in the context of the present invention, capital letters C, G, U, A, and T represent the base composition of nucleotides. In the present invention, a, g, c, and u are 2'-O-methyl (2'-OMe) A, 2'-OMe G, 2'-OMe C, and 2'-OMe U, respectively; Af, Cf, Gf, and Uf are 2'-fluoro A, 2'-fluoro C, 2'-fluoro G, and 2'-fluoro U, respectively; s represents that the nucleotide has a 5'-phosphorothioate modification; Agn (i.e., GNA) is an adenosine-diol nucleic acid, and Tgn represents a thymine-diol nucleotide residue, whose structure is
[0132] In the context of the present invention, Bz stands for benzoyl; MMTr stands for 4'-methoxytrityl; DMTr stands for 4',4'-dimethoxytriphenylmethyl.
[0133] In the present invention, "phosphate group", "phosphoester group", "phosphoester bond" can be used interchangeably, including phosphate monoester, phosphodiester or phosphotriester. "Phosphate group" in "phosphorothioate group" also has the same meaning. Unless otherwise specified, the phosphate group between natural nucleotides is a phosphodiester group.
[0134] The term "oxo" refers to a =0 group. For example, a carbon atom is connected to an oxygen atom via a double bond, wherein a ketone or aldehyde group is formed.
[0135] As used herein, "chemically modified" or "modification" means a structure that is chemically different when compared to a naturally occurring counterpart, including all changes by chemical means, such as the addition or removal of a chemical moiety, or the substitution of one chemical moiety for another.
[0136] The compounds of the present invention may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure forms or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
[0137] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, separation of enantiomers and diastereomers is usually accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with chemical derivatization (e.g., carbamate formation from an amine).
[0138] The present invention also includes isotopically labeled compounds of the present invention which are identical to those described herein, but in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that may be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C, 13C, 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.
[0139] Unless otherwise indicated, when a position is specifically designated as deuterium (D), the position is understood to have deuterium (i.e., at least 10% deuterium incorporation) at least 1000 times greater than the natural abundance of deuterium (which is 0.015%). The natural abundance of the compound in the example may be at least 1000 times greater than deuterium, at least 2000 times greater than deuterium, at least 3000 times greater than deuterium, at least 4000 times greater than deuterium, at least 5000 times greater than deuterium, at least 6000 times greater than deuterium or more. The present invention also includes various deuterated forms of the formula (I) compound. Each available hydrogen atom connected to a carbon atom may be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of the formula (I) compound with reference to the relevant literature. In preparing the deuterated form of the compound of formula (I), commercially available deuterated starting materials may be used, or they may be synthesized using conventional techniques using deuterated reagents, including but not limited to deuterated borane, trideuterated borane in tetrahydrofuran, deuterated lithium aluminum hydride, deuterated iodoethane and deuterated iodomethane.
[0140] The conjugated groups of the present invention can enhance the delivery of therapeutic agents to specific target locations (e.g., specific organs or tissues) in objects such as humans or animals. In some embodiments of the present invention, the conjugated groups can enhance the targeted delivery of expression inhibitory oligonucleotides. In some embodiments of the present invention, the conjugated groups can enhance the delivery of expression inhibitory oligonucleotides to the liver.
[0141] The conjugated groups of the present invention can be directly or indirectly connected to a compound, such as a therapeutic agent, for example, an expression inhibitory oligonucleotide, for example, the 3' or 5' end of an expression inhibitory oligonucleotide. In some embodiments of the present invention, the expression inhibitory oligonucleotide includes one or more modified nucleotides. In some embodiments of the present invention, the expression inhibitory oligonucleotide is an RNAi agent, such as a double-stranded RNAi agent comprising a sense strand and an antisense strand. In some embodiments of the present invention, the conjugated groups disclosed herein are connected to the 3' end of the sense strand of the double-stranded RNAi agent. In some embodiments, the conjugated groups disclosed herein are connected to the expression inhibitory oligonucleotide agent at the 3' end of the sense strand of the double-stranded RNAi agent via a phosphate, a thiophosphate or a phosphonate group.
[0142] Unless otherwise specified, "conjugation" refers to the covalent linkage of two or more chemical moieties, each with a specific function, to each other; accordingly, "conjugate" refers to a compound formed by covalent linkage of the chemical moieties.
[0143] The double-stranded siRNA conjugate of the present invention is a compound formed by connecting the double-stranded siRNA and a pharmaceutically acceptable conjugation group, and the double-stranded siRNA and the pharmaceutically acceptable conjugation group are covalently linked.
[0144] The definitions and conventions of stereochemistry used in this invention are generally based on the following references: SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist in different stereoisomers. All stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, constitute a part of the present invention. Many organic compounds exist in optically active forms, that is, they have the ability to rotate the plane of plane polarized light. When describing optically active compounds, the prefixes D, L or R, S are used to indicate the absolute configuration of the chiral center of the molecule. The prefixes d, l or (+), (-) are used to name the sign of rotation of plane polarized light of a compound. (-) or l means that the compound is levorotatory, and the prefix (+) or d means that the compound is dextrorotatory. The chemical structures of these stereoisomers are identical, but their stereostructures are different. Specific stereoisomers can be enantiomers, and a mixture of isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may result in no stereoselectivity or stereospecificity during chemical reactions. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that lacks optical activity.
[0145] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be interconverted via a low energy barrier. For example, proton tautomers (i.e., prototropic tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine isomerizations.
[0146] The term "composition" refers to a mixture of a drug and other chemical components containing one or more compounds described herein or their physiologically pharmaceutically acceptable salts or precursors, as well as other components such as physiologically pharmaceutically acceptable carriers and excipients. The purpose of the composition is to facilitate administration to an organism, facilitate the absorption of the active ingredients, and thus exert biological activity.
[0147] The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable excipient" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the U.S. Food and Drug Administration for use in humans or domestic animals.
[0148] Unless otherwise specified, the "compound", "ligand", "nucleic acid ligand conjugate" and "nucleic acid" of the present invention may independently exist in the form of salt, mixed salt or non-salt (such as free acid or free base). When it exists in the form of salt or mixed salt, it may be a pharmaceutically acceptable salt.
[0149] The term "acceptable salt" includes acceptable acid addition salts and pharmaceutically acceptable base addition salts. "Acceptable acid addition salt" refers to salts formed with inorganic or organic acids that can retain the biological effectiveness of free bases without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, etc.; organic acid salts include, but are not limited to, formates, acetates, 2,2-dichloroacetates, trifluoroacetates, propionates, caproates, caprylates, decanoates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamates, pyroglutamates, aspartates, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginate, ascorbates, salicylates, 4-aminosalicylates, naphthalene disulfonates, etc. These salts can be prepared by methods known in the art.
[0150] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts, preferably sodium salts. The salt derived from organic base includes but is not limited to the following salt: primary amines, secondary amines and tertiary amines, substituted amines, including natural substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine. These salts can be prepared by methods known in the art.
[0151] As described herein, the compounds of the present invention may optionally be substituted with one or more substituents, such as the general formula compounds above, or as specific examples in the embodiments, subclasses, and classes of compounds encompassed by the present invention. In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced by a specific substituent. Unless otherwise indicated, an optional substituted group may have a substituent substituted at each substitutable position of the group. When more than one position in a given structural formula can be substituted with one or more substituents selected from a specific group, the substituents may be substituted at each position in the same or different manner.
[0152] In addition, it should be noted that, unless explicitly stated otherwise, the description methods used throughout this article, "each... and... are independently", "... and... are each independently", and "... and... are respectively independently" are interchangeable and should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.
[0153] In the present invention, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or situation can but does not necessarily occur, and the description includes cases where the event or situation occurs and cases where it does not occur.
[0154] In various parts of this specification, the substituents of the compounds disclosed in the present invention are disclosed according to group types or ranges. It is particularly pointed out that the present invention includes each independent subcombination of the individual members of these group types and ranges. For example, the term "C 1-6 "Alkyl" refers specifically to methyl, ethyl, C 3 Alkyl, C 4 Alkyl, C 5 Alkyl and C 6 alkyl.
[0155] The term "alkyl" used in the present invention includes saturated straight or branched monovalent hydrocarbon groups of 1 to 20 carbon atoms, wherein the alkyl group may be independently optionally substituted with one or more substituents described in the present invention. In some embodiments, the alkyl group contains 1 to 12 carbon atoms, in other embodiments, the alkyl group contains 1 to 10 carbon atoms, in other embodiments, the alkyl group contains 1 to 8 carbon atoms, in other embodiments, the alkyl group contains 1 to 6 carbon atoms, in other embodiments, the alkyl group contains 1 to 4 carbon atoms, and in other embodiments, the alkyl group contains 1 to 3 carbon atoms. Further examples of alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), n-propyl (n-Pr, -CH 2 CH 2 CH 3 ), isopropyl (i-Pr, -CH (CH 3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), 2-methylpropyl or isobutyl (i-Bu, -CH 2 CH(CH 3 ) 2 ), 1-methylpropyl or sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3), 3-pentyl (-CH(CH 2 CH 3 ) 2 ), 2-methyl-2-butyl (-C(CH 3 ) 2 CH 2 CH 3 ), 3-methyl-2-butyl (-CH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-1-butyl (-CH 2 CH 2 CH(CH 3 ) 2 ), 2-methyl-1-butyl (-CH 2 CH(CH 3 )CH 2 CH 3 ), n-hexyl (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 3 ), 2-hexyl (-CH(CH 3 )CH 2 CH 2 CH 2 CH 3 )、3-hexyl(-CH(CH 2 CH 3 )(CH 2 CH 2 CH 3 ))、2-methyl-2-pentyl (-C(CH 3 ) 2 CH 2 CH 2 CH 3 ), 3-methyl-2-pentyl (-CH(CH 3 )CH(CH 3 )CH 2 CH 3 ), 4-methyl-2-pentyl (-CH(CH 3 )CH 2 CH(CH 3 ) 2 ), 3-methyl-3-pentyl (-C(CH 3 )(CH 2 CH 3 ) 2 ), 2-methyl-3-pentyl (-CH(CH 2 CH 3 )CH(CH3 ) 2 )、2,3-dimethyl-2-butyl (-C(CH 3 ) 2 CH(CH 3 ) 2 )、3,3-dimethyl-2-butyl (-CH(CH 3 )C(CH 3 ) 3 ), n-heptyl, n-octyl, n-nonyl, n-heptyl, and the like.
[0156] The term "alkylene" means a saturated divalent or polyvalent hydrocarbon radical obtained by removing two from a saturated straight or branched hydrocarbon radical. Unless otherwise specified, an alkylene group contains 1-12 carbon atoms. In some embodiments, an alkylene group contains 1-6 carbon atoms; in other embodiments, an alkylene group contains 1-4 carbon atoms; in still other embodiments, an alkylene group contains 1-3 carbon atoms; in still other embodiments, an alkylene group contains 1-2 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), isopropylidene (-CH(CH 3 )CH 2 -), n-propylene (-CH 2 CH 2 CH 2 -), n-butylene (-CH 2 CH 2 CH 2 CH 2 -), sec-butylene (s-Bu, -CH(CH 3 )CH 2 CH 2 -), n-pentylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -), 2-pentylene (-CH(CH 3 )CH 2 CH 2 CH 2 -), n-hexylene (-CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -), 2-hexyl (-CH(CH 3 )CH 2 CH 2 CH2 CH 2 -), n-heptyl (-(CH 2 ) 7 -), octylene (-(CH 2 ) 8 -), nonyl (-(CH 2 ) 9 -), chlorobenzene (-(CH 2 ) 10 -)、-(CH 2 ) 11 -、-(CH 2 ) 12 -、-(CH 2 ) 13 -、-(CH 2 ) 14 -,etc.
[0157] The term "heteroalkyl" used in the present invention means the insertion of 1, 2, 3, 4, 5 or 6 heteroatoms in the alkyl group, wherein the heteroatoms are selected from S, N, NH, O or P, and the sulfur atom can be optionally oxidized to S-oxide. Some embodiments are that the heteroalkyl group contains 1-12 carbon atoms, other embodiments are that the heteroalkyl group contains 1-10 carbon atoms, other embodiments are that the heteroalkyl group contains 1-8 carbon atoms, other embodiments are that the heteroalkyl group contains 1-6 carbon atoms, other embodiments are that the heteroalkyl group contains 1-4 carbon atoms, and other embodiments are that the heteroalkyl group contains 1-3 carbon atoms. Examples of heteroalkyl groups include, but are not limited to CH 3 O-、CH 3 CH 2 O-、CH 3 CH 2 CH 2 O-、CH 3 CH 2 CH 2 CH 2 O-、CH 3 CH 2 OCH 2 -、CH 3 OCH 2 CH 2 -、CH 3 CH 2 CH 2 OCH 2 -、CH 3 CH 2 OCH 2 CH 2 -、CH 3 OCH 2 CH2 CH 2 -、CH 3 S-、CH 3 CH 2 S-、CH 3 CH 2 CH 2 S-、CH 3 CH 2 CH 2 CH 2 S-、CH 3 CH 2 SCH 2 -、CH 3 SCH 2 CH 2 -、CH 3 CH 2 CH 2 SCH 2 -、CH 3 CH 2 SCH 2 CH 2 -、CH 3 SCH 2 CH 2 CH 2 -、CH 3 NH-、CH 3 CH 2 NH-、CH 3 CH 2 CH 2 NH-、CH 3 CH 2 CH 2 CH 2 NH-、CH 3 CH 2 NHCH 2 -、CH 3 NHCH 2 CH 2 -、CH 3 CH 2 CH 2 NHCH 2 -、CH 3 CH 2 NHCH 2 CH 2 -、CH 3 NHCH 2 CH 2 CH 2 - etc.
[0158] The term "alkoxy" means an alkyl group attached to the rest of the molecule via an oxygen atom, wherein the alkyl group has the meaning as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-8 carbon atoms; in other embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; in yet other embodiments, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents described herein.
[0159] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH 3 ), ethoxy (EtO, -OCH 2 CH 3 ), 1-propoxy (n-PrO, n-propoxy, -OCH 2 CH 2 CH 3 )、2-propoxy(i-PrO,i-propoxy,-OCH(CH 3 ) 2 )、1-butoxy(n-BuO,n-butoxy,-OCH 2 CH 2 CH 2 CH 3 ), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH 2 CH(CH 3 ) 2 ), 2-butoxy(s-BuO,s-butoxy,-OCH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propoxy(t-BuO,t-butyloxy,-OC(CH 3 ) 3 ), 1-pentyloxy (n-pentyloxy, -OCH 2 CH 2 CH 2 CH 2 CH 3 ), 2-pentyloxy (-OCH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyloxy (-OCH(CH 2 CH 3 ) 2 ), 2-methyl-2-butoxy (-OC(CH 3 ) 2 CH 2CH 3 ), 3-methyl-2-butoxy(-OCH(CH 3 )CH(CH 3 ) 2 ), 3-methyl-l-butoxy (-OCH 2 CH 2 CH(CH 3 ) 2 ), 2-methyl-1-butoxy (-OCH 2 CH(CH 3 )CH 2 CH 3 )etc.
[0160] The term "alkenyl" refers to a linear or branched monovalent, divalent or polyvalent hydrocarbon group containing 2 to 12 carbon atoms, or 2 to 8 carbon atoms, or 2 to 6 carbon atoms, or 2 to 4 carbon atoms, wherein at least one position of CC is sp 2 double bond, wherein the alkenyl group may be independently unsubstituted or substituted with one or more substituents described herein, including "cis", "trans" or "Z", "E" isomers, specific examples of which include, but are not limited to, vinyl (-CH=CH 2 ), propenyl (-CH=CHCH 3 ), allyl (-CH 2 CH=CH 2 ), wherein the alkenyl groups may independently be unsubstituted or substituted with one or more substituents described herein.
[0161] The term "alkynyl" refers to a linear or branched monovalent or divalent hydrocarbon group of 2 to 12 carbon atoms, wherein at least one CC is an sp triple bond, wherein the alkynyl group can be independently and optionally substituted by one or more substituents described in the present invention, wherein some embodiments are alkynyl groups containing 2 to 12 carbon atoms, other embodiments are alkynyl groups containing 2 to 8 carbon atoms, other embodiments are alkynyl groups containing 2 to 6 carbon atoms, and other embodiments are alkynyl groups containing 2 to 4 carbon atoms. Specific examples include, but are not limited to, ethynyl (-C≡CH), propargyl (-CH 2 C≡CH), propynyl (-C≡C-CH 3 ), butylene (-CH 2 CH 2 C≡CH, -CH 2 C≡CCH 3 、-C≡CCH 2 CH 3 and -CH(CH 3 )C≡CH) and pentyl (-CH 2CH 2 CH 2 C≡CH, -CH 2 CH 2 C≡CCH 3 、-CH 2 C≡CCH 2 CH 3 、-C≡CCH 2 CH 2 CH 3 、-CH 2 CH(CH 3 )C≡CH, -CH(CH 3 )CH 2 C≡CH), -C(CH 3 ) 2 C≡CH, -CH(CH 3 )C≡CCH 3 、-C≡CCH(CH 3 )CH 3 and -C≡CCH(CH 3 ) 2 )etc.
[0162] The term "cycloalkyl" refers to a monovalent or polyvalent saturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 carbon atoms. In one embodiment, the cycloalkyl contains 3 to 12 carbon atoms; in another embodiment, the cycloalkyl contains 3 to 8 carbon atoms; in another embodiment, the cycloalkyl contains 3 to 7 carbon atoms; in yet other embodiments, the cycloalkyl contains 3 to 6 carbon atoms. Examples of cycloalkyl further include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
[0163] The term "MM 1 "consisting of ring atoms" means that the cyclic group is composed of MM 1 The term "heterocyclic group" refers to a group consisting of 3-6 ring atoms, wherein the ring atoms include carbon atoms and / or heteroatoms such as O, N, S, and P. For example, "a heterocyclic group consisting of 3-6 ring atoms" refers to a monoheterocyclic group consisting of 3, 4, 5, or 6 ring atoms.
[0164] The term "heterocyclyl" refers to a non-aromatic, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system containing 3-12 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur or oxygen atom. The heterocyclyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, the heterocyclyl group may be a carbon group or a nitrogen group, and -CH 2-group may be optionally replaced by -C(=O)- or -C(=S)-. The sulfur atom of the ring may be optionally oxidized to S-oxide. The nitrogen atom of the ring may be optionally oxidized to N-oxide. In some embodiments, the heterocyclic group is a heterocyclic group consisting of 3-12 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 5-10 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 3-6 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 4-6 ring atoms, in some embodiments, the heterocyclic group is a heterocyclic group consisting of 5-6 ring atoms, in other embodiments, the heterocyclic group is a heterocyclic group consisting of 4 atoms, refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 4 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclic group is a 5-atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 5 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In other embodiments, the heterocyclic group is a 6-atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated, non-aromatic monocyclic ring containing 6 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. "Heterocyclic group" also includes a group formed by fusion of a heterocyclic group with a saturated or partially unsaturated ring or a heterocyclic ring. Examples of heterocycles include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, glycidyl, azepanyl, oxetanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3- pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolane, pyrazolinyl, dithianyl, dithiolanyl, dihydrothienyl, pyrazolidinylimidazolinyl, imidazolidinyl, 1,2,3,4-tetrahydroisoquinolinyl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[4.1.0]heptyl, azabicyclo[2.2.2]hexyl, 3H-indolylquinolizinyl and N-pyridylurea. Examples of heterocyclic groups also include 1,1-dioxothiomorpholinyl, examples in which the carbon atoms on the ring are replaced by oxo (=O) include, but are not limited to, pyrimidinedione, 1,2,4-thiadiazole-5(4H)-one, 1,2,4-oxadiazole-5(4H)-one, 1H-1,2,4-triazole-5(4H)-one, and the like, examples in which the carbon atoms on the ring are replaced by a =S group include, but are not limited to, 1,2,4-oxadiazole-5(4H)-thione, 1,3,4-oxadiazole-2(3H)-thione, and the like.
[0165] The term "heteroatom" means one or more O, S, N, P and Si, including any oxidation state of N, S and P; in the form of primary, secondary, tertiary amines and quaternary ammonium salts; or in the form of a nitrogen atom in a heterocyclic ring in which the hydrogen is substituted, for example, N (such as N in 3,4-dihydro-2H-pyrrolyl), NH (such as NH in pyrrolidinyl) or NR (such as NR in N-substituted pyrrolidinyl, wherein R represents a substituent as described in the present invention).
[0166] The term "aryl" refers to a monocyclic, bicyclic or tricyclic carbon ring system containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system comprises a ring consisting of 3-7 atoms and has one or more points of attachment to the rest of the molecule. The term "aryl" can be used interchangeably with the term "aromatic ring". Examples of aryl groups can include phenyl, naphthyl and anthracenyl. The aryl groups can be independently and optionally substituted with one or more substituents described herein.
[0167] The terms "alkylsilyl" and "alkylsilyl" refer to a methylsilyl group (-SiH 3 ) groups are independently substituted by 1, 2 or 3 alkyl groups. In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-12 In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-9 In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-6 In some embodiments, the alkylsilyl group is 1, 2 or 3 C 1-4 Alkyl groups are connected to silicon atoms to form lower alkylsilyl groups. In still other embodiments, alkylsilyl groups are 1, 2 or 3 C 1-3 An alkyl group is a lower alkylsilyl group formed by connecting an alkyl group to a silicon atom. Suitable alkylsilyl groups may be monoalkylsilyl, dialkylsilyl or trialkylsilyl. Examples of alkylsilyl groups include, but are not limited to, trimethylsilyl (-Si(CH 3 ) 3 ), triethylsilyl (-Si(CH 2 CH 3 ) 3 ), tri-n-propylsilyl (-Si(CH 2 CH 2 CH 3 ) 3 )etc.
[0168] The term "hydroxy protecting group" refers to an unstable chemical moiety that protects the hydroxyl group from undesirable reactions during one or more synthetic procedures. After the one or more synthetic procedures, the hydroxy protecting group can be selectively removed. Hydroxy protecting groups known in the art are generally described in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, New York (1999). Examples of hydroxy protecting groups of the present invention include, but are not limited to, C 1-10 alkylmethyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropoxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl (Ac or -C(O)CH 3 ), formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl (Bz or -C(O)C 6 H 5 ), C 1-10 Alkyl (methyl, tert-butyl, etc.), 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, C 6-10 Aryl C 1-4 Alkyl (such as benzyl, phenethyl, etc.), p-methoxybenzyldiphenylmethyl, triphenylmethyl (triphenylmethyl or trityl), tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, p-toluenesulfonyl, C 1-10 Alkylsilyl (such as trimethylsilyl (TMS or -Si(CH 3 ) 3 )), triethylsilyl, triisopropylsilyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl, etc.
[0169] The term "amino protecting group" refers to an unstable chemical moiety that protects the amino group from undesirable reactions during the synthesis procedure. After the one or more synthesis procedures, the amino protecting group as described herein can be selectively removed. Amino protecting groups as known in the art are generally described in TH Greene and PGM Wuts, Protective Groups in Organic Synthesis, the 3rd edition, John Wiley & Sons, New York (1999). The example of amino protecting group includes but is not limited to acetyl, tert-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl and benzyloxycarbonyl etc.
[0170] The term "solid support" specifically refers to any particle, bead or surface on which oligonucleotide synthesis can occur. For example, inorganic solid supports and organic solid supports can be selected for use in embodiments of the present invention. Inorganic solid supports are preferably selected from silica gel and controlled-pore glass beads (Controlled-pore glass, CPG for short). Organic solid supports are resins, preferably macroporous resins, more preferably highly cross-linked polystyrene, Tentagel (graft copolymers composed of low cross-linked polystyrene matrix, polyethylene glycol (PEG or POE) grafted thereon), polyvinyl acetate (PVA), copolymers of Poros (Poros)-polystyrene / divinylbenzene, aminopolyethylene glycol and cellulose etc. Preferred embodiments of the present invention utilize solid supports based on CPG. Many other purchasable solid supports all belong to the present invention.
[0171] Unless otherwise specified, A in the general formula of the present invention 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 , B 1 , B 2 , B 3 , B 4 , B 5 , C 5 , Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , L 1 , L 2 、F 1 、F 2 、F 3 , L3 , D 1 , D 2 and D 3 is a divalent linking group; Ring A is a trivalent linking group.
[0172] When the Markush variables involved in the general formulas of the present invention need to be used as linking groups, the groups listed for the Markush variables should be understood as linking groups. 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 , B 1 , B 2 , B 3 , B 4 , B 5 , C 5 , Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , L 1 , L 2 、F 1 、F 2 、F 3 , L 3 , D 1 , D 2 and D 3 It should be understood as a linking group, and the linking groups involved, such as "cycloalkyl", "heterocyclyl", "heteroalkyl", "alkenyl" and "alkynyl" should respectively represent divalent linking groups such as "cycloalkylene", "heterocyclylene", "heteroalkylene", "alkenylene" and "alkynylene". BRIEF DESCRIPTION OF THE DRAWINGS
[0173] Attached Figure 1 The graph is a graph showing the inhibitory effects of the siRNA conjugates DAW30221, DAW30222 and DAW30223 of the present invention and the control conjugate DAW30025 on HBsAg in a Tg / HBV mouse model experiment.
[0174] Attached Figure 2 The figure is a curve diagram showing the knockdown effect of the siRNA conjugate DAW30255 of the present invention on AGT in a mouse model experiment.
[0175] Detailed description of the compounds of the present invention
[0176] The present invention provides a new targeting compound, which can be used to prepare a nucleic acid drug for targeted delivery of oligonucleotides to the liver. The present invention also provides a nucleotide conjugate, a preparation method and an application thereof, which has a higher in vivo delivery efficiency, better stability, higher gene expression inhibition activity in hepatocytes and / or lower toxicity. On the other hand, the present invention further provides an siRNA reagent, a preparation method and an application thereof, which has a higher in vivo delivery efficiency, better stability, higher gene expression inhibition activity in HBV and / or lower toxicity.
[0177] In one aspect, the present invention relates to a compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I),
[0178]
[0179] Among them, each Z, Y, ring A, L 1 , L 2 , L 3 and R have the meanings as defined in the present invention.
[0180] In some embodiments of the compounds of the present invention, Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms.
[0181] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(═O)(CH 2 ) j C(=O)- or MC(=O)(CH 2 ) j C(=O)-, wherein each M and j has the meanings described in the present invention.
[0182] In some embodiments of the compounds of the present invention, Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(═O)(CH 2 ) j C(=O)- or MC(=O)(CH 2 ) j C(=O)-, wherein the hydroxyl protecting group is an ester protecting group, an alkoxyalkyl protecting group, a silyl protecting group, a substituted or unsubstituted aryl protecting group, or a substituted or unsubstituted arylalkyl protecting group, wherein each M and j has the meaning described in the present invention.
[0183] In some embodiments of the compounds of the invention, each j is independently 1, 2, 3, 4 or 5.
[0184] In some embodiments of the compounds of the invention, M is a solid support.
[0185] In some embodiments of the compounds of the present invention, M is a hydroxyl- or amino-functionalized solid support.
[0186] In some embodiments of the compounds of the present invention, M is a resin or CPG.
[0187] In some embodiments of the compounds of the invention, M is a macroporous resin or CPG.
[0188] In some embodiments of the compounds of the invention, M is an aminomethyl resin, a hydroxy resin or CPG.
[0189] In some embodiments of the compounds of the invention, M is an aminomethyl resin, a hydroxy resin, an aminoCPG, or a hydroxyCPG.
[0190] In some embodiments of the compounds of the invention, M is an aminomethyl resin, a hydroxy resin, or -NHCPG.
[0191] In some embodiments of the compounds of the present invention, each L 1 , L 2 and L 3 Independently for C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 Has the meaning described in the present invention.
[0192] In some embodiments of the compounds of the present invention, R is a structure represented by the following formula (a) or formula (b):
[0193]
[0194] Among them, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , Y 1 , Y 2 , Y 3 , Y4 , Y 5 , A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Has the meaning described in the present invention.
[0195] In some embodiments of the compounds of the present invention, wherein each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 and X 15 is independently H or a hydroxy protecting group.
[0196] In some embodiments of the compounds of the present invention, wherein each Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is independently H or an amino protecting group.
[0197] In some embodiments of the compounds of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 Has the meaning described in the present invention.
[0198] In some embodiments of the compounds of the present invention, each B 1 , B 2 , B 3 , B 4 and B 5 Independently for C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein B 1 and B 2 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3 to 12 ring atoms, B 3 , B 4 and B 5 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, wherein each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 Has the meaning described in the present invention.
[0199] In some embodiments of the compounds of the present invention, each L 1 , L 2 and L 3 Independently for C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1)C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0200] In some embodiments of the compounds of the present invention, each L 1 , L 2 and L 3 Independently for C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1)-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0201] In some embodiments of the compounds of the present invention, each L1 , L 2 and L 3 Independently for C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0202] In some embodiments of the compounds of the present invention, each L 1 , L 2 and L 3 Independently for C 3-6 alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-6 alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0203] In some embodiments of the compounds of the present invention, each L 1 , L 2 and L 3 Independently -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of the -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 )6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -、C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0204] In some embodiments of the compounds of the present invention, each L 1 , L 2 and L 3 Independently -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12-, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of the -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -、C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0205] In some embodiments of the compounds of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0206] In some embodiments of the compounds of the present invention, each A 1 , A 2 , A3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl or C 2-8 Alkynyl, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0207] In some embodiments of the compounds of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C2 , C 3 , C 4 and C 5 Independently for the key, C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1)-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0208] In some embodiments of the compounds of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-6 alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-6 alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0209] In some embodiments of the compounds of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 are independently a bond, -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH 2 ) 4 NHCH 2 -、-O(CH 2 ) 3 NHCH 2 -、-O(CH 2 ) 5 NHCH 2 -、-O(CH 2 ) 4 NH-, -O(CH 2 ) 3 NH-, -O(CH 2 ) 5 NH-, -CH 2 O(CH 2 ) 4 NH-, -CH 2 O(CH 2 ) 3 NH-, -CH 2 O(CH 2 ) 2 NH-、C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5-、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH 2 ) 4 NHCH 2 -、-O(CH 2 ) 3 NHCH 2 -、-O(CH 2 ) 5 NHCH 2 -、-O(CH 2 ) 4 NH-, -O(CH 2 ) 3 NH-, -O(CH 2 ) 5 NH-, -CH 2 O(CH 2 ) 4 NH-, -CH 2 O(CH 2 ) 3 NH-, -CH 2 O(CH 2 ) 2 NH-、C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Substitution, each of the -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-O(CH 2 ) 4 NHCH 2 -、-O(CH 2 ) 3 NHCH 2 -、-O(CH 2 ) 5 NHCH2 -、-O(CH 2 ) 4 NH-, -O(CH 2 ) 3 NH-, -O(CH 2 ) 5 NH-, -CH 2 O(CH 2 ) 4 NH-, -CH 2 O(CH 2 ) 3 NH-, -CH 2 O(CH 2 ) 2 NH-、C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0210] In some embodiments of the compounds of the present invention, each B 1 , B 2 , B 3 , B 4 or B 5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein B 1 and B 2At least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3 to 6 ring atoms, B 3 , B 4 and B 5 At least one of them is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W3 Has the meaning described in the present invention.
[0211] In some embodiments of the compounds of the present invention, each B 1 , B 2 , B 3 , B 4 or B 5 are independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4Alkenyl or C 2-4 Alkynyl, wherein B 1 and B 2 At least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, 3 , B 4 and B 5 At least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W3 Has the meaning described in the present invention.
[0212] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkyl methyl, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0213] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkyl methyl, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 )j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0214] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkyl methyl, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j have the meanings described in the present invention.
[0215] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkyl methyl, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2 ) j C(=O)-, MC(=O)(CH 2 ) j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j has the meanings described in the present invention.
[0216] In some embodiments of the compounds of the invention, Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl , 2-(4-(6-methyl-1-oxo)-1-yl ... 1-4 Alkyl methyl, C 1-4 Alkylsilyl, phenylmethyl, phenylethyl, HOC(=O)(CH 2 ) j C(=O)-, MC(=O)(CH 2 ) j C(═O)—, triphenylmethyl, MMTr, DMTr or 4′,4′,4′-trimethoxytrityl, wherein each M and j has the meanings described in the present invention.
[0217] In some embodiments of the compounds of the present invention, the ring A is a heterocyclic group consisting of 3 to 7 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0218] In some embodiments of the compounds of the present invention, the ring A is a heterocyclic group consisting of 3 to 6 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0219] In some embodiments of the compounds of the invention, Ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0220] In some embodiments of the compounds of the present invention, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-, where R 2 Has the meaning described in the present invention.
[0221] In some embodiments of the compounds of the present invention, each Y 1 , Y 2 , Y 3 , Y 4 and Y 5 are independently H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-, where R 3 Has the meaning described in the present invention.
[0222] In some embodiments of the compounds of the present invention, each R 2 and R 3 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl.
[0223] In some embodiments of the compounds of the present invention, each R 2 and R3 Independently for C 1-4 Alkyl, halogenated C 1-6 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl.
[0224] In some embodiments of the compounds of the present invention, each R 2 and R 3 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, tert-butoxy, 2-methyl-1-propoxy, 2-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl.
[0225] In some embodiments of the compounds of the present invention, each R 1 are independently H, deuterium or C 1-6 alkyl.
[0226] In some embodiments of the compounds of the present invention, each R 1 are independently H, deuterium or C 1-4 alkyl.
[0227] In some embodiments of the compounds of the present invention, each R 1 is independently H, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
[0228] In some embodiments of the compounds of the present invention, each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
[0229] In some embodiments of the compounds of the present invention, each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-4 Alkyl, C 1-4 Alkoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0230] In some embodiments of the compounds of the present invention, each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0231] In some embodiments of the compounds of the present invention, R is a structure represented by the following formula (a-1) or formula (b-1):
[0232] Among them, each X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , A 1 , A 2 , A 3 , A 4 , A 5 , B 1 , B 2 , B 3 , B 4 , B 5 , C 1 , C 2 , C 3 , C 4 and C 5 Has the meaning described in the present invention.
[0233] In some embodiments, the compound of the present invention has a structure as shown in formula (II), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II).
[0234] Among them, each Z, Y, L1 , L 2 , L 3 and R have the meanings as defined in the present invention.
[0235] In some embodiments, the compound of the present invention has a structure as shown in formula (II-1), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II-1).
[0236] Among them, each Z, Y, L 1 , L 2 , L 3 and R have the meanings as defined in the present invention.
[0237] In some embodiments, the compound of the present invention has a structure as shown in formula (II-2), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II-2).
[0238] Among them, each Z, Y, L 1 , L 2 , L 3 and R have the meanings as defined in the present invention.
[0239] In some embodiments, the compound of the present invention has a structure as shown in formula (III), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (III).
[0240]
[0241] Among them, each D 1 , D 2 and D 3 are independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH 2 - * or -N(R 1 )C(=O)CH 2 - * ;
[0242] Each F 1 、F 2 and F 3are independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl;
[0243] Each n 1 、n 2 、n 3 、m 1 、m 2 、m 3 and m 4 are independently 0, 1, 2, 3 or 4,
[0244] Among them, each R 1 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , Y 3 , Y 4 , Y 5 , Z and Y have the meanings described in the present invention.
[0245] In some embodiments of the compounds of the present invention, the present invention has one of the compounds shown below, or a stereoisomer, tautomer or acceptable salt thereof,
[0246]
[0247]
[0248]
[0249]
[0250]
[0251]
[0252] M is a solid support, preferably a hydroxyl or amino functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin, an aminoCPG or a hydroxyCPG; further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG.
[0253] On the other hand, the present invention relates to a conjugated group comprising a structure as shown in formula (Ia), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (Ia),
[0254]
[0255] Among them, each ring A, L 1 , L 2 , L 3 and R x Has the meaning described in the present invention.
[0256] In some embodiments of the conjugate group of the present invention, R x It is a structure of formula (c) or formula (d):
[0257]
[0258] Each A 1 , A 2 , A 3 , A 4 , A 5 , B 1 , B 2 , B 3 , B 4、 B 5 , C 1 , C 2 , C 3 , C 4 , C 5 , Y 1 , Y 2 , Y 3 , Y 4 and Y 5 The definitions of have the meanings set forth in the present invention.
[0259] In some embodiments of the conjugated group of the present invention, Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms.
[0260] In some embodiments of the conjugated group of the present invention, the ring A is a heterocyclic group consisting of 3 to 7 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0261] In some embodiments of the conjugated group of the present invention, the ring A is a heterocyclic group consisting of 3 to 6 atoms or a cycloalkyl group consisting of 3 to 6 atoms.
[0262] In some embodiments of the conjugated groups of the present invention, the ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
[0263] In some embodiments of the conjugate group of the present invention, each L 1 , L2 and L 3 Independently for C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1)C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 Has the meaning described in the present invention.
[0264] In some embodiments of the conjugate groups of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1)S(=O) 2 - and -N(R 1 )-, wherein each R 1 Has the meaning described in the present invention.
[0265] In some embodiments of the conjugate group of the present invention, each B 1 , B 2 , B 3 , B 4 and B 5 Independently for C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein B 1 and B 2 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3 to 12 ring atoms, B 3 , B 4 and B 5 At least one of them is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, wherein each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 Has the meaning described in the present invention.
[0266] In some embodiments of the conjugate group of the present invention, each L 1 , L 2 and L 3 Independently for C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1)-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0267] In some embodiments of the conjugate group of the present invention, each L 1 , L 2 and L 3 Independently for C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1Replace, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0268] In some embodiments of the conjugate group of the present invention, each L 1 , L 2 and L 3 Independently for C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0269] In some embodiments of the conjugate group of the present invention, each L 1 , L 2 and L 3 Independently for C 3-6 alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-6 alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W1Has the meaning described in the present invention.
[0270] In some embodiments of the conjugate group of the present invention, each L 1 , L 2 and L 3 Independently -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each -(CH 2 ) 3 -、-(CH 2 ) 4-、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of the -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -、C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0271] In some embodiments of the conjugate group of the present invention, each L 1 , L 2 and L 3 Independently -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1)C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Substitution, each of the -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-(CH 2 ) 9 -、-(CH 2 ) 10 -、-(CH 2 ) 11 -、-(CH 2 ) 12 -、C 2-10 Heteroalkyl, C2-10 Alkenyl and C 2-10 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W1 Has the meaning described in the present invention.
[0272] In some embodiments of the conjugate groups of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0273] In some embodiments of the conjugate groups of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl or C 2-8 Alkynyl, wherein each C 3-10 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-8 Heteroalkyl, C 2-8 Alkenyl and C 2-8 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-10 Alkylene, C 2-8 Heteroalkyl, C 2-8 Alkenyl, C 2-8The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0274] In some embodiments of the conjugate groups of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1)C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-8 Alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclic group consisting of 3-6 ring atoms, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-8 Alkylene, C 2-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0275] In some embodiments of the conjugate groups of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 Independently for the key, C 3-6alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each C 3-6 alkylene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-6 Alkylene, C 2-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -and-N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0276] In some embodiments of the conjugate groups of the present invention, each A 1 , A 2 , A 3 , A 4 , A 5 , C 1 , C 2 , C 3 , C 4 and C 5 are independently a bond, -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH 2 ) 4 NHCH 2 -、-O(CH 2 ) 3 NHCH 2 -、-O(CH 2 ) 5 NHCH 2 -、-O(CH 2 ) 4 NH-, -O(CH 2 ) 3 NH-, -O(CH 2 ) 5 NH-, -CH 2 O(CH 2 ) 4 NH-, -CH 2 O(CH2 ) 3 NH-, -CH 2 O(CH 2 ) 2 NH-、C 2-6 Alkenyl, C 2-6 Alkynyl, -O-, -S-, -S(=O)-, -S(=O) 2 -、-S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 -or-N(R 1 )-, wherein each -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, -O(CH 2 ) 4 NHCH 2 -、-O(CH 2 ) 3 NHCH 2 -、-O(CH 2 ) 5 NHCH 2 -、-O(CH 2 ) 4 NH-, -O(CH 2 ) 3 NH-, -O(CH2 ) 5 NH-, -CH 2 O(CH 2 ) 4 NH-, -CH 2 O(CH 2 ) 3 NH-, -CH 2 O(CH 2 ) 2 NH-、C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Substitution, each of the -(CH 2 ) 3 -、-(CH 2 ) 4 -、-(CH 2 ) 5 -、-(CH 2 ) 6 -、-(CH 2 ) 7 -、-(CH 2 ) 8 -、-O(CH 2 ) 4 NHCH 2 -、-O(CH 2 ) 3 NHCH 2 -、-O(CH 2 ) 5 NHCH 2 -、-O(CH 2 ) 4 NH-, -O(CH 2 ) 3 NH-, -O(CH 2 ) 5 NH-, -CH 2 O(CH 2 ) 4 NH-, -CH 2 O(CH 2 ) 3 NH-, -CH 2 O(CH 2 ) 2 NH-、C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W2 Has the meaning described in the present invention.
[0277] In some embodiments of the conjugate group of the present invention, each B 1 , B 2 , B 3 , B 4 or B 5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein B 1 and B 2 At least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3 to 6 ring atoms, B 3 , B 4 and B 5 At least one of them is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)-2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W3 Has the meaning described in the present invention.
[0278] In some embodiments of the conjugate group of the present invention, each B 1 , B 2 , B 3 , B 4 or B 5 are independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl or C 2-4 Alkynyl, wherein B 1 and B 2 At least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, 3 , B 4 and B 5 at least one of them is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, each of the cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl, C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C2-4 Alkynylcyclopropyl is optionally substituted by 1, 2, 3 or 4 R W3 Replace, each C 1-4 Alkylene, C 1-4 Heteroalkyl, C 2-4 Alkenyl and C 2-4 The 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)- 2 -, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O) 2 N(R 1 )-、-N(R 1 )S(=O) 2 - and -N(R 1 )-, wherein each R 1 and R W3 Has the meaning described in the present invention.
[0279] In some embodiments of the conjugate groups of the present invention, each R 1 are independently H, deuterium or C 1-6 alkyl.
[0280] In some embodiments of the conjugate groups of the present invention, each R 1 are independently H, deuterium or C 1-4 alkyl.
[0281] In some embodiments of the conjugate groups of the present invention, each R 1 is independently H, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
[0282] In some embodiments of the conjugate groups of the present invention, each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C1-6 Heteroalkyl.
[0283] In some embodiments of the conjugate groups of the present invention, each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-4 Alkyl, C 1-4 Alkoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0284] In some embodiments of the conjugate groups of the present invention, each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
[0285] In some embodiments of the conjugated group of the present invention, R x It is a structure shown in the following formula (c-1) or formula (d-1):
[0286] Among them, each A 1 , A 2 , A 3 , A 4 , A 5 , B 1 , B 2 , B 3 , B 4、 B 5 , C 1 , C 2 , C 3 , C 4 , C 5 , Y 1 , Y 2 , Y 3 , Y 4 and Y 5 The definitions of have the meanings set forth in the present invention.
[0287] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a),
[0288]
[0289] Among them, each R x , L 1 , L 2 and L 3 The definitions of have the meanings set forth in the present invention.
[0290] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a-1), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a-1),
[0291]
[0292] Among them, each L 1 , L 2 , L 3 and R x It has the meaning described in the present invention.
[0293] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (II-a-2), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a-2),
[0294]
[0295] Among them, each L 1 , L 2 , L 3 and R x It has the meaning described in the present invention.
[0296] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has a structure as shown in formula (III-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (III-a),
[0297]
[0298] Among them, each D 1 , D 2 and D 3 are independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- *、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH 2 - * or -N(R 1 )C(=O)CH 2 - * ;
[0299] Each F 1 、F 2 and F 3 are independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl;
[0300] Each n 1 、n 2 、n 3 、m 1 、m 2 、m 3 and m 4 are independently 0, 1, 2, 3 or 4,
[0301] Among them, each R 1 , Y 1 , Y 2 , Y 3 , Y 4 and Y 5 The definitions of have the meanings set forth in the present invention.
[0302] In some embodiments of the conjugated group of the present invention, the conjugated group of the present invention has one of the structures shown below, or a stereoisomer, a tautomer or an acceptable salt thereof,
[0303]
[0304]
[0305] In another aspect, the present invention relates to a nucleic acid conjugate, which comprises the conjugation group of the present invention and a nucleic acid, wherein the nucleic acid is a modified or unmodified nucleic acid.
[0306] In some embodiments of the nucleic acid conjugates of the present invention, the nucleic acid is linked to the conjugated group via a phosphate group, a thiophosphate group or a phosphate group.
[0307] In some embodiments of the nucleic acid conjugate of the present invention, the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid, preferably siRNA; optionally, the conjugated group is preferably conjugated to the 3' end or 5' end of the sense strand of the siRNA, and more preferably to the 3' end of the sense strand of the siRNA.
[0308] In some embodiments of the nucleic acid conjugates of the present invention, the conjugated group is conjugated to the 3' end or the 5' end of the nucleic acid.
[0309] In another aspect, the present invention also relates to a siRNA nucleic acid conjugate, which is one of DAW30223, DAW30062, DAW30219, DAW30221, DAW30222 and DAW30255,
[0310] DAW30223:
[0311] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40002-4 (SEQ ID NO: 2)
[0312] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0313] DAW30062:
[0314] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40003-4 (SEQ ID NO: 3)
[0315] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0316] DAW30219:
[0317] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40004-4 (SEQ ID NO: 4)
[0318] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0319] DAW30221:
[0320] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40005-4 (SEQ ID NO: 5)
[0321] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0322] DAW30222:
[0323] Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40007-4 (SEQ ID NO: 6)
[0324] Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ ID NO: 7)
[0325] DAW30255:
[0326] Sense strand (5'-3'): gs-us-cauc-Cf-a-Cf-Af-Af-ugagaguaca-DAW40007-4 (SEQ ID NO: 8)
[0327] Antisense strand (5'-3'): us-Gfs-uac-(Tgn)-cucauug-Uf-g-Gf-auga-cs-gs-a (SEQ ID NO: 9).
[0328] In some embodiments, the conjugate groups DAW40002-4, DAW40003-4, 40004-4, DAW40005-4 and DAW40007-4 described in the present invention are each conjugated to the 3' end of the siRNA sense strand via a phosphate group, and the structures thereof are shown below:
[0329]
[0330]
[0331] In another aspect, the present invention relates to a pharmaceutical composition comprising the siRNA conjugate of the present invention and a pharmaceutically acceptable carrier.
[0332] On the other hand, the present invention also relates to the use of the compound, the conjugated group or the nucleic acid conjugate of the present invention in the preparation of a drug for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0333] In some embodiments, the present invention also relates to the use of the compound and the conjugated group described in the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0334] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of small nucleic acid drugs in vivo.
[0335] In some embodiments of the use of the present invention, the compound or the conjugated group is used for liver-targeted delivery of siRNA drugs or ASO drugs in vivo.
[0336] In some embodiments, the present invention also relates to the use of the nucleic acid conjugates of the present invention in drug delivery for treating and / or preventing pathological conditions or diseases caused by the expression of specific genes in hepatocytes.
[0337] In some embodiments of the use of the present invention, the specific gene includes, but is not limited to, ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0338] In some embodiments of the use of the present invention, the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
[0339] On the other hand, the present invention also relates to the use of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222 described in the present invention and a composition comprising DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222 described in the present invention and a pharmaceutically acceptable carrier in the preparation of a medicament for treating and / or preventing hepatitis B disease.
[0340] On the other hand, the present invention also relates to use of DAW30255 or a composition thereof described in the present invention in the preparation of a medicament for treating and / or preventing hypertension.
[0341] On the other hand, the present invention also provides a method for inhibiting the expression of a specific gene in liver cells in a patient, which comprises administering the nucleic acid conjugate or a composition thereof of the present invention to the patient, wherein the nucleic acid conjugate or the composition thereof may be a therapeutically effective amount.
[0342] In some embodiments of the present invention, the nucleic acid (or small nucleic acid) of the present invention refers to siRNA or ASO.
[0343] On the other hand, the present invention also provides a method for inhibiting the expression of a specific gene in liver cells in a patient, which comprises administering the siRNA body conjugate or a composition thereof of the present invention to the patient, wherein the nucleic acid ligand conjugate or the composition thereof may be a therapeutically effective amount.
[0344] Nucleic acid conjugates, preparations, administration and disease treatment methods of nucleic acid conjugates of the present invention
[0345] The effective amount of the nucleic acid conjugate (such as siRNA conjugate or pharmaceutical composition) of the present invention may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated by the patient, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment situation, several divided doses may be administered daily, for example, four times a day, three times a day, twice a day, once a day, or once every other day, or several doses administered daily may be proportionally reduced.
[0346] The drug can be administered to a subject by any suitable route known in the art, including but not limited to oral or parenteral routes, including intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, airway administration (aerosol), pulmonary administration, nasal administration, rectal administration and topical administration (including buccal administration and sublingual administration), preferably intravenous injection.
[0347] The pharmaceutical composition disclosed in the present invention includes preparations suitable for parenteral administration. The preparation can be conveniently present in unit dosage form and can be prepared by any method known in the pharmaceutical field. The amount of active ingredient that can be combined with auxiliary materials to prepare a single dose form is generally the amount of siRNA that produces a therapeutic effect. Generally speaking, in units of one percent, the amount is about 1% to about 99% active ingredient, preferably about 5% to about 70%, and most preferably about 10% to about 30%.
[0348] In another aspect of the present invention, the present invention proposes a method for inhibiting the expression or activity of hepatitis B virus genes. According to an embodiment of the present invention, the method comprises: contacting the aforementioned siRNA, the aforementioned siRNA conjugate or the aforementioned pharmaceutical composition with cells. As mentioned above, the aforementioned siRNA and siRNA conjugate can degrade the mRNA of hepatitis B virus and inhibit the expression and replication of HBV. Therefore, the method of the present invention can be used to inhibit the expression or activity of hepatitis B virus genes. For example, the expression or activity of hepatitis B virus genes can be inhibited in animals; or the expression or activity of hepatitis B virus genes can be inhibited for non-disease treatment purposes, such as inhibiting the expression or activity of hepatitis B virus genes in vitro for subsequent research.
[0349] In another aspect of the present invention, the present invention provides a method for preventing and / or treating hepatitis B virus-induced diseases. According to an embodiment of the present invention, the method comprises: administering a pharmaceutically acceptable amount of the aforementioned siRNA, the aforementioned siRNA conjugate, or the aforementioned pharmaceutical composition to a subject. According to an embodiment of the present invention, the method can effectively prevent and / or treat diseases related to hepatitis B virus-induced diseases.
[0350] General synthesis method of the compound and nucleic acid conjugate of the present invention
[0351] Generally, the compounds and nucleic acid conjugates of the present invention can be prepared by the methods described in the present invention, unless otherwise specified, wherein the substituents are defined as shown in formula (I), (II), (II-1), (II-2), (III), (Ia), (II-a), (II-a-1), (II-a-2), (III-a). The following reaction schemes and examples are used to further illustrate the content of the present invention.
[0352] In the following examples, all temperatures are in degrees Celsius (°C) unless otherwise indicated. The chromatographic column used was a silica gel column, and the silica gel (200-300 mesh) was purchased from Qingdao Ocean Chemical Plant, NH 2 CPG was purchased from Hebei Dinaxingke. Nuclear magnetic resonance spectroscopy was performed with CDC1 3 DMSO-d 6 , CD 3 OD or acetone-d 6is the solvent (in ppm), TMS (0 ppm) or chloroform (7.25 ppm) is used as the reference standard. When multiple peaks appear, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), dd (doublet of doublets), dt (doublet of triplets), br.s (broadened singlet), q (quartet). The coupling constant J is expressed in Hertz (Hz).
[0353] Low-resolution mass spectrometry (MS) data were determined by an Agilent 6320 series LC-MS spectrometer equipped with a G1312A binary pump and a G1316A TCC (column temperature was maintained at 30 °C). A G1329A autosampler and a G1315B DAD detector were used for analysis, and an ESI source was applied to the LC-MS spectrometer.
[0354] High-resolution mass spectrometry (MS) data were determined by an Agilent 6130 series LC-MS spectrometer equipped with a G1311A quaternary pump and a G1316A TCC (column temperature was maintained at 30 °C). A G1329A autosampler and a G1315D DAD detector were used for analysis, and an ESI source was applied to the HR-MS spectrometer.
[0355] The following abbreviations are used throughout this invention:
[0356] EDCI 1-ethyl-3 (3-dimethylpropylamine) carbodiimide EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HOBT 1-Hydroxybenzotriazole EA Ethyl acetate
[0357] TFA Trifluoroacetic acid HOBT 1-Hydroxybenzotriazole
[0358] Py Pyridine DMAP 4-Dimethylaminopyridine
[0359] PE Petroleum ether MsCl Methanesulfonyl chloride
[0360] ACN Acetonitrile TMSOTf Trimethylsilyl trifluoromethanesulfonate Ac 2 O Acetic anhydride THF Tetrahydrofuran
[0361] Boc tert-butyloxycarbonyl mL milliliter
[0362] MeOH methanol min minutes
[0363] DMSO dimethyl sulfoxide M,N,mol / L mole / liter DMF N,N-dimethylformamide h hours
[0364] DCM dichloromethane RT, rt room temperature
[0365] DIPEA N,N-Diisopropylethylamine
[0366] HBTU Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate DETAILED DESCRIPTION
[0367] The scheme of the present invention will be explained below in conjunction with the examples. Those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. In particular, the synthesis of small nucleic acids and the synthesis of nucleic acid conjugates can be synthesized according to the embodiments of the present invention or the routine adjustments in the field. If the specific techniques or conditions are not indicated in the examples, they are carried out according to the techniques or conditions described in the literature in the field or according to the product instructions. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0368] Synthesis method of the compound of the present invention
[0369] The following synthesis scheme lists the general experimental steps for preparing the compounds disclosed in the present invention, including those skilled in the art can make appropriate method modifications or raw material adjustments according to actual conditions to prepare the compounds of the present invention. 7 , X 8 , X 9 , D 1 、F 1 、n 1 , Y 3 , L 1 , L 2 , L 3 、m 1 、m 2 、m 3 and R have the meanings as described in the present invention. Unless otherwise specified, the compounds described in the present invention can be prepared by the methods described in the following synthesis schemes.
[0370] Synthesis Scheme 1:
[0371]
[0372]
[0373] The compound represented by formula (A-4) can be prepared by the method described in Synthesis Scheme 1, wherein Q is an amino protecting group, such as Cbz, Boc, etc. Compound (A-1) is deprotected from the amino protecting group Q to obtain compound (A-2); compound (A-2) and compound (A-3) undergo condensation reaction to obtain compound (A-4).
[0374] Synthesis Scheme 2:
[0375]
[0376] The compound represented by formula (a-5) can be prepared by the method described in Synthesis Scheme 2, wherein L 1 One end of the benzyloxy group contains a carbonyl group. Compound (a-1) is freed of the benzyl group to obtain compound (a-2); compound (a-2) undergoes a condensation reaction with compound 13 to obtain compound (a-3); compound (a-3) reacts with succinic anhydride to obtain compound (a-4); compound (a-4) reacts with a solid support to obtain compound (a-5).
[0377] Preparation Example
[0378] In the following preparation examples, the inventors describe in detail the preparation process of the compounds of the present invention by taking some of the compounds of the present invention as examples, wherein: For CPG.
[0379] Example 1: Compound DAW40003-3
[0380]
[0381]
[0382] Step 1: Synthesis of compound 3
[0383] Compound 1 (2.42 g, 19.98 mmol) and sodium hydroxide (0.40 mL, 2.00 mmol) were dissolved in DMSO (4 mL), and compound 2 (8.96 g, 69.93 mmol) was slowly added, and the mixture was stirred at room temperature for 36 h. The solvent was then evaporated under reduced pressure, and the residue was chromatographed on a silica gel column (PE / EA (V / V) = 1 / 2 + 0.05% concentrated ammonia water) to obtain a light yellow oily compound 3 (4.61 g, 45.64%). MS (ESI, pos.ion) m / z: 506.4 [M+H] + .
[0384] Step 2: Synthesis of compound 5
[0385] Compound 4 (prepared by the synthetic method of compound 76 in WO2020093053A1) (0.15 g, 0.47 mmol), HBTU (0.23 g, 0.60 mmol) and DIPEA (0.16 g, 1.20 mmol) were dissolved in DMF (1 mL), stirred at room temperature for 5 min, and then compound 3 (0.20 g, 0.40 mmol) was added and stirred for 16 h. After the reaction was completed, it was diluted with water (10 mL), extracted with DCM (2×50 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a light yellow viscous compound 5 (0.32 g, 100.12%), which was directly used for the next step. MS (ESI, pos.ion) m / z: 404.5 [M / 2+H] + .
[0386] Step 3: Synthesis of compound 6
[0387] Compound 5 (0.30 g, 0.37 mmol) was dissolved in TFA (3 mL) and stirred at room temperature for 3 h. The solvent was evaporated under reduced pressure, purified by C18 reverse phase preparative chromatography column (acetonitrile / water (V / V) = 1 / 1 to 5 / 1 + 0.1% TFA), and lyophilized under reduced pressure to obtain white solid compound 6 (0.20 g, 84.21%). MS (ESI, pos.ion) m / z: 640.3 [M+H] + .
[0388] Step 4: Synthesis of compound 8
[0389] Compound 6 (0.15 g, 0.23 mmol), compound 7 (0.15 g, 0.81 mmol), EDCI (0.19 g, 0.97 mmol) and HOBT (0.13 g, 0.97 mmol) were dissolved in DCM (3 mL) and stirred at room temperature for 15 h. Water (5 mL) was added to quench the reaction, and then DCM (40 mL) was added to dilute it. The mixture was washed with hydrochloric acid solution (20 mL, 1 M), saturated sodium bicarbonate (10 mL) and saturated sodium chloride solution (10 mL) in sequence, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 10 / 1 to 5 / 1) to obtain a light yellow viscous compound 8 (0.26 g, 96.81%). MS (ESI, pos.ion) m / z: 1144.7 [M+H] + .
[0390] Step 5: Synthesis of compound 9
[0391] Compound 8 (0.26 g, 0.23 mmol) was dissolved in TFA (5 mL) and stirred at room temperature for 5 h. The solvent was evaporated under reduced pressure to obtain a light yellow viscous compound 9 (0.27 g), which was directly used for the next step. MS (ESI, pos.ion) m / z: 844.8 [M+H] + .
[0392] Step 6: Synthesis of compound 11
[0393] Compound 10 (0.10 g, 0.23 mmol) (purchased from Lingkai Pharmaceuticals), HBTU (0.33 g, 0.87 mmol), HOBT (0.12 g, 0.87 mmol) and DIPEA (0.30 g, 2.30 mmol) were dissolved in DMF (2 mL) and stirred at room temperature for 5 min, followed by the slow addition of a DMF (1 mL) solution of compound 9 (0.27 g) obtained in step 5, and the mixture was stirred at room temperature for 19 h. After the reaction was completed, DCM (100 mL) was added for dilution, and then the mixture was washed with saturated sodium bicarbonate solution (100 mL) and saturated brine (100 mL) in sequence, the organic phase was dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 20 / 1 to 5 / 1) to obtain a slightly yellow solid compound 11 (0.39 g, 80.42%). MS (ESI, pos.ion) m / z: 2131.0 [MH] + .
[0394] Step 7: Synthesis of compound 12
[0395] Compound 11 (0.11 g, 0.052 mmol) and palladium / carbon (0.0055 g, 0.0052 mmol, 10%) were added to methanol (5 mL), and the reaction system was replaced with hydrogen three times, and then stirred at room temperature for 8 h under a hydrogen atmosphere. After the reaction, the mixture was filtered through diatomaceous earth and the filtrate was evaporated under reduced pressure to obtain a yellow-brown oily compound 12 (0.10 g, 94.92%), which was directly used in the next step. MS (ESI, pos.ion) m / z: 2041.0 [MH] - .
[0396] Step 8: Synthesis of compound DAW40003-1
[0397] Compound 12 (0.28 g, 0.14 mmol), HBTU (0.058 g, 0.15 mmol) and DIPEA (0.062 g, 0.48 mmol) were dissolved in DCM (2 mL), stirred at room temperature for 5 min, and then a solution of compound 13 (0.059 g, 0.14 mmol) in DCM (1 mL) was slowly added dropwise. Stir at room temperature for 12 h. The solvent was evaporated under reduced pressure, and the residue was dissolved in DMF (5 mL) and separated by reverse preparative column (acetonitrile / water solution (V / V) = 43% to 49% + 0.1% ammonium acetate). Salt was added to the preparatively separated product-containing solution to saturate it, and the organic phase was separated. The aqueous phase was extracted with acetonitrile (2×100 mL), the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a light yellow solid compound DAW40003-1 (0.18 g, 53.72%). MS (ESI, pos.ion) m / z: 2442.0 [MH] - .
[0398] Step 9: Synthesis of compound DAW40003-2
[0399] Under nitrogen protection, compound DAW40003-1 (0.45 g, 0.19 mmol), succinic anhydride (0.022 g, 0.22 mmol), DMAP (0.032 g, 0.26 mmol) and DIPEA (0.048 g, 0.37 mmol) were dissolved in DCM (2 mL) and stirred at room temperature for 41.5 h. After the reaction, it was diluted with DCM (100 mL), then washed with saturated sodium bicarbonate solution (20 mL) and saturated brine (20 mL) in sequence, the organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a light yellow viscous compound DAW40003-2 (0.19 g, 40.56%), which was directly used in the next step. MS (ESI, pos.ion) m / z: 2542.2 [MH] + .
[0400] Step 10: Synthesis of compound DAW40003-3
[0401] Compound DAW40003-2 (0.18 g, 0.071 mmol), HBTU (0.040 g, 0.11 mmol) and DIPEA (0.024 mL, 0.14 mmol) were dissolved in ACN (5 mL) and stirred at room temperature for 5 min. The mixture was then transferred to a flask containing 0.7 g H 2 N-CPG (purchased from Hebei Dinaxingke) was shaken in a solid phase synthesizer for 22.5 hours. The filter cake was filtered and washed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL) respectively. The filter cake was dried and diluted with 25% Ac 2The mixture was reacted in an O / Py solution (5 mL) for 3 h and then filtered. The filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10 mL) and DCM (10 mL) in sequence and dried under reduced pressure to obtain a white solid DAW40003-3 (0.67 g). The loading capacity was measured to be 29.39 μmol / g.
[0402] Example 2: Compound DAW40004-3
[0403]
[0404]
[0405] Step 1: Synthesis of compound 17
[0406] Compound 16 (2.00 g, 9.94 mmol) and triethylamine (3.02 g, 29.82 mmol) were dissolved in DCM (20 mL), and methanesulfonyl chloride (1.37 g, 11.93 mmol) was added dropwise to the solution under ice bath, and the reaction mixture was stirred at room temperature for 31 h. After the reaction, DCM (100 mL) and dilute hydrochloric acid (0.2 M, 20 mL) were added in sequence, and the organic phase was separated, washed with saturated brine (2×50 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain a light yellow solid compound 17 (2.64 g, 95.1%). MS (ESI, pos.ion) m / z: 302.4 [M+Na] + .
[0407] Step 2: Synthesis of compound 18
[0408] Compound 17 (2.50 g, 8.95 mmol) and sodium azide (1.16 g, 17.9 mmol) were added to DMF (40 mL), stirred at 70 ° C for 21 h, cooled to room temperature, EA (300 mL) and water (200 mL) were added, the organic phase was separated, washed with saturated brine (2×200 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain an oily substance, which was cooled to obtain a white solid compound 18 (2.0 g, 98.76%). MS (ESI, pos.ion) m / z: 227.1 [M+H] + .
[0409] Step 3: Synthesis of compound 19
[0410] 18 (0.53 g, 2.34 mmol) and triphenylphosphine (0.92 g, 3.51 mmol) were dissolved in tetrahydrofuran (11.5 mL) and water (0.23 mL) and stirred at room temperature for 10 h. After the reaction, the reaction solution was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to obtain a slightly yellow viscous compound 19 (0.44 g, 93.8%). MS (ESI, pos.ion) m / z: 201.3 [M+H] + .
[0411] Step 4: Synthesis of compound 21
[0412] Compound 10 (1.11 g, 2.48 mmol), HOBT (0.46 g, 3.38 mmol) and HBTU (1.28 g, 3.38 mmol) were dissolved in DMF (5 mL), stirred at 25 ° C for 5 min, and then a solution of compound 19 (0.45 g, 2.25 mmol) in DMF (1 mL) was slowly added dropwise, followed by DIPEA (2.61 mL, 15.75 mmol). The reaction mixture was reacted at room temperature for 18 h. After the reaction, DCM (200 mL) was added for dilution, and the mixture was washed with saturated sodium bicarbonate solution (20 mL), brine (5%, 100 mL×2) and saturated brine (50 mL) in sequence. The organic phase was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (MeOH / DCM (V / V) = 1 / 5) to obtain white solid compound 21 (0.85 g, 60.08%). MS (ESI, pos.ion) m / z: 630.7 [M+H] + .
[0413] Step 5: Synthesis of compound 22
[0414] Compound 21 (3.4 g, 5.4 mmol) was dissolved in DCM (54 mL), and then TFA (4.01 mL, 54 mmol) was added. The reaction mixture was stirred at room temperature for 5 h. The solvent was evaporated under reduced pressure to obtain a slightly yellow oil 22 (3.47 g, 102.3%). MS (ESI, pos.ion) m / z: 530.1 [M+H] + .
[0415] Step 6: Synthesis of compound 23
[0416] Compound 23 was prepared by the synthetic method of step 6 of reference example 1, as a white solid (1.6 g, 47%). MS (ESI, pos.ion) m / z: 2173.0588 [MH] - .
[0417] Step 7: Synthesis of compound 24
[0418] Compound 24 was prepared by the synthetic method of step 7 of reference example 1, as a white solid (1.53 g, 84.21%). MS (ESI, pos.ion) m / z: 1042.3 [M / 2+H] + .
[0419] Step 8: Synthesis of compound DAW40004-1
[0420] Compound DAW40004-1 was prepared by the synthetic method of step 8 of reference example 1, and was a light yellow solid (0.40 g, 33.5%). MS (ESI, pos.ion) m / z: 2484.2 [M+H] + .
[0421] Step 9: Synthesis of compound DAW40004-2
[0422] Compound DAW40004-2 was prepared by the synthetic method of step 9 of reference example 1, and was a white solid (0.4 g, 96.13%). MS (ESI, pos.ion) m / z: 1291.6 [M / 2+H] + .
[0423] Step 10: Synthesis of compound DAW40004-3
[0424] Compound DAW40004-3 was prepared by the synthetic method of step 10 of reference example 1, and was white solid DAW40004 (1.59 g), with a measured loading of 25.94 μmol / g.
[0425] Example 3: DAW40005-3
[0426]
[0427] Step 1: Synthesis of compound 28
[0428] Compound 27 (1.52 g, 3.5 mmol) (prepared according to the synthetic method in Journal of Organic Chemistry (2020), 85 (10), 6593-6604), HOBT (0.71 g, 5.25 mmol) and HBTU (1.99 g, 5.25 mmol) were dissolved in DMF (10 mL), stirred at 25 °C for 5 min, and then a solution of compound 19 (0.7 g, 3.5 mmol) in DMF (2 mL) was slowly added dropwise, followed by the addition of DIPEA (2.9 mL, 17.5 mmol), and the reaction mixture was reacted at room temperature for 16 h. Water (30 mL) was added to dilute, then extracted with EA (50 mL × 4), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel column chromatography (DCM to MeOH / DCM (V / V) = 1 / 10) to obtain a white solid compound 28 (1.24 g, 57.63%). MS (ESI, pos.ion) m / z: 616.6 [M+H] + .
[0429] Step 2: Synthesis of compound 29
[0430] Compound 28 (0.60 g, 0.97 mmol) was dissolved in DCM (8 mL), then TFA (0.72 mL, 9.7 mmol) was added, the reaction mixture was stirred at room temperature for 5 h, and the solvent was evaporated under reduced pressure to obtain a brown oil compound 29 (0.60 g, 97.95%). MS (ESI, pos.ion) m / z: 516.6 [M+H] + .
[0431] Step 3: Synthesis of compound 30
[0432] Compound 6 (0.19 g, 0.30 mmol), compound 29 (0.66 g, 1.05 mmol), HOBT (0.17 g, 1.26 mmol), HBTU (0.48 g, 1.26 mmol) and DIPEA (0.50 mL, 3 mmol) were dissolved in DCM (20 mL), stirred at room temperature for 16 h, water (20 mL) was added to quench the reaction, extracted with DCM (100 mL × 2), washed with saturated sodium bicarbonate (40 mL) and saturated sodium chloride solution (40 mL) in sequence, dried over anhydrous sodium sulfate, evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 10 / 1) to obtain white solid compound 30 (0.275 g, 43.42%). MS (ESI, pos.ion) m / z: 1066.7 [M / 2+H] + .
[0433] Step 4: Synthesis of compound 31
[0434] Compound 31 was prepared by the synthetic method of step 7 of reference example 1, as a white solid (0.26 g, 98.72%). MS (ESI, pos.ion) m / z: 1022.5 [M / 2+H] + .
[0435] Step 5: Synthesis of compound DAW40005-1
[0436] Compound DAW40005-1 was prepared by the synthetic method of step 8 of reference example 1, and was a light yellow solid (0.08 g, 25.8%). MS (ESI, neg.ion) m / z: 2442.1 [MH] - .
[0437] Step 6: Synthesis of compound DAW40005-2
[0438] Compound DAW40005-2 was prepared by the synthetic method of step 9 of reference example 1, and was a white solid (0.08 g, 96.07%). MS (ESI, pos.ion) m / z: 2542.2 [MH] - .
[0439] Step 7: Synthesis of compound DAW40005-3
[0440] Compound DAW40005-3 was prepared by the synthetic method of step 10 of reference example 1, and was a white solid (0.22 g) with a measured loading of 22.32 μmol / g.
[0441] Example 4: DAW40002-3
[0442]
[0443]
[0444] Step 1: Synthesis of compound 35
[0445] Compound 34 (2.50 g, 28.05 mmol) and triethylamine (7.8 mL, 56.1 mmol) were dissolved in DCM (120 mL), and benzyl chloroformate (9.57 g, 56.1 mmol) was added dropwise at 0°C. After the addition, the reaction mixture was heated to room temperature and stirred for 20 h, and saturated ammonium chloride solution (50 mL) was added for dilution, the liquids were separated, the aqueous phase was discarded, the organic phase was concentrated, and the residue was purified by silica gel column chromatography (MeOH / DCM (V / V) = 1 / 30) to obtain white solid compound 35 (2.96 g, 47.2%).
[0446] MS (ESI, pos.ion) m / z: 224.2 [M+H] + ;
[0447] 1 H NMR (400 MHz, CDCl 3 )δ7.37(d,J=4.2Hz,5H),5.11(s,2H),5.00(s,1H),4.19–4.14(m,1H),3.70–
[0448] 3.64(m,2H),3.24(t,J=6.4Hz,2H),3.15(q,J=4.6Hz,1H),1.90(dq,J=14.2,5.0,4.3Hz,2H),1.77–1.71(m,1H).
[0449] Step 2: Synthesis of compound 37
[0450] Compound 36 (1.5 g, 4.56 mmol) and compound 35 (1.22 g, 5.47 mmol) were dissolved in 1,2-dichloroethane (30 mL), and 3A molecular sieves (2.0 g) were added and stirred at room temperature for 10 min. TMSOTf (0.51 g, 2.28 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. The reaction solution was poured into a saturated sodium bicarbonate solution (100 mL), then extracted with DCM (100 mL), washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA (V / V) = 2 / 1 to EA) to obtain a light brown oil compound 37 (1.8 g, 71.51%). MS (ESI, pos.ion) m / z: 553.3 [M+H] + .
[0451] Step 3: Synthesis of compound 38
[0452] Compound 37 (0.57 g, 1.03 mmol) and palladium carbon (0.11 g, 0.1 mmol, 10%) were added to THF (10 mL), and then TFA (0.12 g, 1.03 mmol) was added, followed by hydrogen replacement three times, and then stirred at room temperature for 19 h in a hydrogen atmosphere. After the reaction was completed, the mixture was filtered with celite and the solvent was evaporated under reduced pressure to obtain a light brown oily compound 38 (0.55 g, 100.32%). MS (ESI, pos.ion) m / z: 419.3 [M+H] + .
[0453] Step 4: Synthesis of compound 40
[0454] Compound 39 (0.55 g, 2.55 mmol) and compound 38 (1.45 g, 2.8 mmol) were dissolved in DCM (30 mL), and HBTU (1.50 g, 3.95 mmol) and DIPEA (1.4 mL, 8.47 mmol) were added in sequence. The reaction mixture was reacted at room temperature for 16 h. After the reaction, water (20 mL) and DCM (100 mL) were added in sequence to dilute the mixture. The organic phase was washed with saturated sodium bicarbonate solution (20 mL) and saturated brine (20 mL) in sequence. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (MeOH / EA (V / V) = 1 / 20) to obtain white solid compound 40 (0.60 g, 38%). MS (ESI, pos.ion) m / z: 616.6 [M+H] + .
[0455] Step 5: Synthesis of compound 41
[0456] Compound 40 (0.72 g, 1.17 mmol) was dissolved in DCM (8 mL), TFA (0.87 mL, 11.7 mmol) was added, and the mixture was stirred at 25 °C for 16 h. The solvent was concentrated to obtain a brown oil compound 41 (0.74 g, 100%). MS (ESI, pos.ion) m / z: 516.3 [M+H] + .
[0457] Step 6: Synthesis of compound 42
[0458] Compound 6 (0.30 g, 0.42 mmol, i.e., compound 6 in Example 1, which was prepared by the synthesis method of compound 6 in Example 1) and compound 41 (0.71 g, 1.39 mmol) were dissolved in DCM (30 mL), and HOBT (0.24 mL, 1.76 mmol), HBTU (0.67 g, 1.76 mmol) and DIPEA (0.7 mL, 4.2 mmol) were added, and the reaction mixture was stirred at 30°C for 3 h. Water (20 mL) was added to quench the reaction, and DCM (100 mL×2) was used for extraction. The organic phases were combined, washed with saturated sodium bicarbonate (40 mL) and saturated sodium chloride solution (40 mL) in sequence, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (DCM to DCM / MeOH (V / V=10 / 1)) to obtain white solid compound 42 (0.15 g, 17%). MS(ESI,pos.ion)m / z:1066.2[M / 2+H] + .
[0459] Step 7 to Step 9: Synthesis of Compound 43, Compound DAW40002-1 and Compound DAW40002-2
[0460] Compound 43, compound DAW40002-1 and compound DAW40002-2 were prepared by the synthetic methods of steps 7 to 9 of Example 1, respectively.
[0461] Compound DAW40002-1 is a white solid (0.083 g, 36.5%), HRMS (ESI, neg.ion) m / z: 2442.1905 [MH] - ;
[0462] Compound DAW40002-2 is a white solid (0.08 g, 96.07%), HRMS (ESI, neg.ion) m / z: 2542.1929 [MH] - .
[0463] Step 10: Synthesis of compound DAW40002-3
[0464] Compound DAW40002-3 was prepared by the synthetic method of step 10 of reference example 1 as a white solid (0.35 g) with a measured loading of 21.806 uM / g.
[0465] Example 5: Compound DAW40007-3
[0466]
[0467]
[0468]
[0469] Step 1: Synthesis of compound 46
[0470] Compound 45 (0.46 g, 2.29 mmol, purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.) and compound 38 (1.16 g, 2.18 mmol, i.e., compound 38 in Example 4, which was prepared by the synthetic method of compound 38 in Example 1) were dissolved in DCM (30 mL), and HOBT (0.46 g, 3.44 mmol), HBTU (1.30 g, 3.44 mmol) and DIPEA (2.66 mL, 16.03 mmol) were added in sequence, and the reaction mixture was reacted at room temperature for 16 h. After the reaction, water (20 mL) and DCM (50 mL×2) were added in sequence, and the organic phase was washed with saturated sodium bicarbonate solution (30 mL) and saturated brine (20 mL) in sequence, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (MeOH / EA (V / V) = 1 / 20) to obtain white solid 46 (1.0 g, 72.7%).
[0471] MS (ESI, pos.ion) m / z: 602.3 [M+H] + ;
[0472] 1 H NMR (400MHz, CD 3 OD)δ5.39–5.33(m,1H),5.07(dd,J=11.2,3.4Hz,1H),4.58(d,J=8.4Hz,1H), 4.21–4.09(m,3H),4.04(t,J=6.7Hz,1H),3.89(dt,J=10.4,5.1Hz,1H),3.60– 3.50(m,1H),3.30–3.13(m,2H),2.16(s,3H),2.04(s,3H),1.97(s,3H),1.94( s,3H),1.67–1.56(m,4H),1.48(s,9H),1.41–1.37(m,2H),1.02–0.98(m,2H).
[0473] Step 2: Synthesis of compound 47
[0474] Compound 46 (0.72 g, 1.17 mmol) was dissolved in DCM (8 mL), and then TFA (0.87 mL, 11.7 mmol) was added. The reaction mixture was stirred at 25 °C for 16 h, and the solvent was concentrated to give brown oily compound 47 (0.74 g, 103.1%).
[0475] MS (ESI, pos.ion) m / z: 502.2 [M+H] + ;
[0476] 1 H NMR (400MHz, CD 3 OD)δ5.36(d,J=3.3Hz,1H),5.08(dd,J=11.3,3.3Hz,1H),4.58(d,J=8.4H z,1H),4.16–4.10(m,3H),4.08–4.02(m,1H),3.92–3.85(m,1H),3.58–3.5 0(m,1H),3.26–3.20(m,2H),2.16(s,3H),2.04(d,J=5.2Hz,6H),1.98(s,3 H),1.97(s,3H),1.61–1.56(m,4H),1.54–1.52(m,2H),1.42–1.38(m,2H).
[0477] Step 3: Synthesis of compound 48
[0478] Compound 6 (0.19 g, 0.3 mmol, i.e., compound 6 in Example 1, which was prepared by the synthetic method of compound 6 in Reference Example 1) and compound 47 (0.5 g, 0.99 mmol) were dissolved in DCM (30 mL), and then HOBT (0.17 g, 1.26 mmol), HBTU (0.48 g, 1.26 mmol) and DIPEA (0.5 mL, 3.0 mmol) were added in sequence, and the reaction mixture was stirred at 30°C for 3 h. After the reaction was completed, water (20 mL) was added to quench the reaction, and then extracted with DCM (100 mL×2), the organic phases were combined, and the organic phases were washed with saturated sodium bicarbonate solution (40 mL) and saturated sodium chloride solution (40 mL) in sequence, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was chromatographed on a silica gel column (DCM to DCM / MeOH (V / V) = 10 / 1) to obtain white solid compound 48 (0.23 g, 37%).
[0479] MS(ESI,pos.ion)m / z:1046.3[M / 2+H] + ;
[0480] 1 H NMR (400MHz, CD 3 OD)δ7.78(t,J=5.8Hz,2H),7.38–7.36(m,3H),5.36(d,J=3.4Hz,3H),5.13(s,2H),5.08(dd,J=11.2,3.4Hz,3H),4 .58(d,J=8.4Hz,3H),4.21–4.08(m,9H),4.04(t,J=6.7Hz,3H),3.93–3.82(m,3H),3.73–3.66(m,12H),3.60–3.52 (m,3H),3.29–3.18(m,6H),2.52(t,J=6.0Hz,6H),2.38(t,J=7.4Hz,2H),2.20(t,J=7.7Hz,2H),2.16(s,9H),2.04 (s,9H),1.97(s,9H),1.95(s,9H),1.62–1.56(m,12H),1.50–1.42(m,6H),1.35–1.27(m,16H),1.04–0.97(m,6H).
[0481] Step 4: Synthesis of compound 49
[0482] Compound 48 (0.20 g, 0.094 mmol) was dissolved in methanol (10 mL), and then Pd / C (10 mg, 10%) was added. The hydrogen was replaced three times, and the reaction mixture was stirred at room temperature for 11 h in a hydrogen atmosphere. After the reaction was completed, the reaction mixture was filtered through diatomaceous earth, and the obtained filtrate was evaporated under reduced pressure to dry the solvent to obtain white solid compound 49 (0.19 g, 100%)
[0483] MS(ESI,pos.ion)m / z:1001.1,[M / 2+H] + .
[0484] Step 5: Synthesis of compound DAW40007-1
[0485] Compound 49 (0.28 g, 0.14 mmol) was dissolved in DCM (20 mL), and HOBT (0.038 g, 0.28 mmol), HBTU (0.080 g, 0.21 mmol), DIPEA (0.054 g, 0.42 mmol) and compound 13 (0.068 g, 0.16 mmol) were added in sequence. The reaction mixture was stirred at room temperature for 13 h. After the reaction was completed, water (10 mL) was added to quench the reaction, and the mixture was extracted with DCM (20 mL). The organic phase was washed with saturated sodium bicarbonate solution (10 mL) and the mixture was heated to 40 ℃. The solvent was evaporated, and the obtained residue was dissolved in acetonitrile (10 mL), and separated by reverse preparative column (acetonitrile / water solution (V / V) = 43% to 60%, 50 min). Salt was added to the solution containing the product after preparative separation to saturate the solution, and the organic phase was separated. The aqueous phase was extracted with acetonitrile (100 mL × 2), and the organic phases were combined. The combined organic phases were dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. Acetonitrile (30 mL) was added to the residue, and then dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a light yellow solid compound DAW40007-1 (0.08 g, 24%).
[0486] MS(ESI,neg.ion)m / z:2400.18[MH] - ;
[0487] 1 H NMR (400 MHz, DMSO-d 6)δ8.31(s,3H),7.81(d,J=9.2Hz,3H),7.57(t,J=6.0Hz,3H),7.35–7.26(m,4H),7.20(td,J=8.9,3.0Hz,5H),6.95(s,1H),6.88(ddd,J=8.8,5.8 ,2.2Hz,4H),5.22(d,J=3.4Hz,3H),4.97(dd,J=11.2,3.5Hz,4H),4.49(d,J=8.5Hz,3H),4.40(d,J=4.8Hz,1H),4.15(s,1H),4.07–4.00(m,9H),3 .88(dt,J=11.2,8.8Hz,3H),3.74(s,9H),3.59–3.48(m,12H),3.17(dd, J=8.8,5.0Hz,1H),3.10–2.95(m,8H),2.35(t,J=6.3Hz,6H),2.10(s,9H) ,2.08(s,3H),2.04(d,J=4.7Hz,2H),2.00(s,9H),1.89(s,9H),1.78(s, 9H), 1.40 (d, J=12.2Hz, 17H), 1.31–1.16 (m, 18H), 0.79 (q, J=3.2Hz, 6H).
[0488] Step 6: Synthesis of compound DAW40007-2
[0489] Compound DAW40007-1 (0.080 g, 0.033 mmol) was dissolved in DCM (10 mL), and DIPEA (0.029 mL, 0.17 mmol), succinic anhydride (0.008 g, 0.083 mmol) and DMAP (0.014 g, 0.12 mmol) were added. The mixture was stirred at 40 °C for 5 h, and succinic anhydride (10 mg) was added. After the reaction was continued for 16 h, DCM (10 mL), succinic anhydride (10 mg) and DIPEA (0.05 mL) were added. The mixture was stirred for another 9 h, and then succinic anhydride (10 mg) was added. After the reaction was continued for another 10 h, DCM (20 mL) was added for dilution, and the mixture was washed with saturated sodium bicarbonate solution (10 mL). The aqueous phase was discarded, and the organic phase was dried over anhydrous sodium sulfate. The solvent was concentrated under reduced pressure to obtain a white solid compound DAW40007-2 (0.08 g, 96.07%). MS(ESI,neg.ion)m / z:2500.12[MH] - .
[0490] 1 H NMR (400 MHz, DMSO-d 6)δ8.45(d,J=6.6Hz,2H),7.85(d,J=9.2Hz,3H),7.62(d,J=5.2Hz,3H),7.37–7.26(m,4H),7.25–7.17(m,5H),7.01(s,1H),6.92–6.83(m,4 H),5.22(d,J=3.4Hz,3H),4.98(dd,J=11.2,3.4Hz,3H),4.50(d,J=8.5Hz,3H),4.24–4.12(m,2H),4.03(s,9H),3.93–3.85(m,4H),3.74(s ,6H),3.72–3.64(m,4H),3.63–3.48(m,13H),3.47–3.38(m,4H),3.28–3.19(m,1H),3.10–3.01(m,6H),2.35(t,J=6.6Hz,8H),2.25–2.17( m,2H),2.11(s,9H),2.07–2.03(m,2H),2.00(s,9H),1.89(s,9H),1.78(s,9H),1.48–1.36(m,16H),1.27–1.15(m,20H),0.82–0.75(m,6H).
[0491] Step 7: Synthesis of compound DAW40007-3
[0492] Compound DAW40007-2 (0.08 g, 0.032 mmol), HBTU (0.015 g, 0.04 mmol) and DIPEA (0.011 mL, 0.064 mmol) were dissolved in ACN (5 mL) and stirred at room temperature for 5 min. Then the mixture was transferred to a flask containing 0.35 g H 2 The solid phase synthesizer of N-CPG (purchased from Hebei Dinaxingke) was shaken for 22.5h. Filtered, the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10mL) and DCM (10mL), and dried. The obtained filter cake was diluted in 25% Ac2O / Py solution (5mL) and stirred for 3h, filtered, and the filter cake was rinsed with DCM / MeOH (V / V=9 / 1, 10mL) and DCM (10mL) in turn, and dried under reduced pressure to obtain a white solid DAW40007-3 (0.357g), with a measured load of 14.95μmol / g.
[0493] Synthesis of compound L96
[0494]
[0495] Compound L96 was prepared according to the method described in patent application WO2014025805A1.
[0496] The structure of the L96 conjugated group is:
[0497]
[0498] In addition, the compound of the present invention is linked to the siRNA molecule according to methods known in the art, and the protection is removed to obtain the siRNA conjugate containing the conjugate group of the present application, such as DAW40007-3 After connecting with siRNA and removing the protecting group, it forms DAW40007-4 siRNA conjugates of conjugated groups (ie, siRNA drugs).
[0499] Example 6: Synthesis of siRNA conjugates
[0500] Antisense strand us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u( SEQ ID NO:7 ) is as follows:
[0501] The synthesis was completed according to the theoretical yield of 1umol. Weigh 1umol of solid support CPG (purchased from Hebei Dinaxingke), 2'-methoxy nucleoside monomer and 2'-fluoro nucleoside monomer (purchased from Wuhu Huaren Technology) and AgN monomer (purchased from Beijing Coupling Technology Co., Ltd.) and provide them in 0.1M anhydrous acetonitrile solution. For oligonucleotides with phosphate backbone thiolation modification, 0.1M DDTT solution was used as the thiolation reagent. 5-Ethylthio-1H-tetrazole acetonitrile solution (0.25M) was used as an activator (purchased from Suzhou Kelema), 0.02M iodine pyridine / water solution was used as an oxidant, and 3% trichloroacetic acid in dichloromethane was used as a deprotection reagent, which was placed in the reagent designated position corresponding to the KA-H8 model DNA / RNA automatic synthesizer. Set the synthesis program and enter the specified oligonucleotide base sequence. After checking that everything is correct, start the cyclic oligonucleotide synthesis. The coupling time for each step is 6 minutes and the sulfurization time is 6 minutes. After automatic circulation, the oligonucleotide containing CPG on the solid support is obtained.
[0502] The nucleotide containing CPG on the solid support obtained above was blown dry with dry argon, then transferred to a 2mL EP tube, and 28% ammonia solution (1.8mL) was added and heated at 55°C for 5 to 18 hours. Filter, wash the filter cake with water (0.5mL), combine the filtrate, and concentrate under reduced pressure to obtain a white or yellow colloidal solid. After reverse phase preparation and purification, the preparation solution was concentrated, passed through a gel column, and excess salt was removed to obtain an oligonucleotide. The concentration of the obtained oligonucleotide was determined by a micro-ultraviolet spectrophotometer (SPECTRO statNano). Mass spectrometry detection and analysis were completed on the Agilent 6530LC-MS Q-Tof system. After primary scanning, the molecular weight of the nucleic acid was calculated after deconvolution. The measured value was consistent with the theoretical value, indicating that the target antisense chain was synthesized.
[0503] Synthesis of siRNA conjugate sense strand:
[0504] The universal solid support CPG was replaced with the GalNAc solid support CPG prepared by the present invention, and the siRNA conjugate sense chain of the present invention was prepared by referring to the antisense chain synthesis method. The measured molecular weight value was consistent with the theoretical value, indicating that the synthesized target siRNA sense chain.
[0505] The HPLC purity and measured molecular weight of the positive strand of some siRNA conjugates are shown in Table 1 below:
[0506] Table 1: HPLC purity and measured molecular weight of the sense strand of siRNA conjugates
[0507]
[0508]
[0509] Annealing step: The sense strand of the siRNA conjugate synthesized above was mixed with the antisense strand synthesized above in equal molar amounts, heated to 95°C, kept at temperature for 10 minutes, and then slowly cooled to room temperature. The target siRNA conjugate was then lyophilized to obtain the target siRNA conjugate, whose number and sequence are shown in Table 2 below.
[0510] Table 2: siRNA conjugate numbers and their corresponding sense strands (containing conjugate groups) and reaction strands
[0511]
[0512] The base letters are lowercase 2'-OMe modified, f is 2'-F modified, s is phosphate backbone thio modified, Agn is adenosine-diol nucleic acid (GNA) modified, Tgn represents a thymine-diol nucleotide residue, DAW40002-4, DAW40003-4, DAW40004-4, DAW40005-4 and DAW40007-4 are the conjugate groups of the present invention, each of which is independently conjugated to the 3' end of the sense chain through a phosphate group.
[0513] Example 7: Hepatitis B virus transgenic mouse experiment
[0514] Experimental methods
[0515] Experimental animals: HBV-Tg transgenic mice, C57B / 6N-Tg(1.28HBV) / Vst, SPF-grade male, 6-8 weeks old, 16-20 g, purchased from Beijing Weitongda Biotechnology Co., Ltd., animal production certificate number: SCXK(Beijing)2019-0002. The animals were raised by Beijing Weitongda Biotechnology Co., Ltd. and were kept in individual cages.
[0516] Animal grouping: According to the quantitative detection results of mouse serum HBsAg (primary) and HBeAg (secondary), the animals were stratified and randomly divided into groups, with 5 animals in each group.
[0517] Preparation and administration of test products: Calculate the required amount of drug powder according to the purity of each test product. Add the corresponding physiological saline according to the administration concentration of 0.6 mg / mL, and oscillate to mix until it becomes a colorless and transparent liquid. The day of the first administration is defined as day 0. All groups of animals were given a single dose on day 0, and the subcutaneous administration volume was 5 mL / kg. If blood sampling is required on the day of animal administration, the administration will be performed after blood sampling.
[0518] Main outcome measures: The subjects were weighed and blood was drawn once on the 3rd, 7th, 14th, 21st, 28th and 35th days, and serum was separated for determination of HBsAg and HBeAg levels.
[0519] Serum HBsAg and HBeAg level determination: After blood collection, serum is separated and diluted with PBS solution before being sent for testing. 10 μL of serum is taken from each sample and diluted to 500 μL (50 times dilution) with PBS solution. Serum HBsAg and HBeAg levels are measured using the Hepatitis B e Antigen Assay Kit (Mike Biotech) and the Hepatitis B Surface Antigen Assay Kit (Mike Biotech), respectively.
[0520] Results of the Hepatitis B Virus Transgenic Mouse Experiment
[0521] The experimental results show that the siRNA conjugates of the present invention can significantly reduce HBsAg in the Tg / HBV mouse model experiment, and compared with the vector L96 used in the four Galnac-siRNAs currently on the market, the siRNA conjugates of the present invention are superior to the siRNA conjugate DAW30025 using L96 in reducing HBsAg while ensuring the same sequence, such as the siRNA conjugates DAW30221, DAW30222 and DAW30 223 (the carriers used, also called conjugated groups, correspond to DAW40002-4, DAW40005-4 and DAW40007-4 respectively) are significantly better than the siRNA conjugate DAW30025 using L96 in reducing HBsAg. The siRNA conjugate of the present invention has a better sustained effect in reducing HBsAg (the inhibitory effects of the conjugates DAW30221, DAW30222, DAW30223 and DAW30025 on HBsAg are shown in the attached Figure 1 ). In addition, the siRNA conjugate of the present invention also has a good inhibitory effect on HBeAg in the Tg / HBV mouse model experiment.
[0522] Example 8: In vivo knockdown activity test of AGT siRNA conjugate in mice
[0523] Experimental methods:
[0524] To evaluate the in vivo activity of the siRNA conjugates coupled to the GalNAc carrier of the present invention on AGT, an AGT humanized mouse model (6 to 9 mice per group) was used. Baseline serum of mice in each group was collected 3 days before administration. A single dose of 1 mg / kg or 3 mg / kg of the GalNAc-siRNA of the present invention or a vehicle was subcutaneously administered at the back of the neck on D0. Blood samples were collected on D4 / 7 / 14 / 21 / 28 / 35 / 49, and human AGT protein concentration was determined by Elisa (ab287170). The knockdown percentage was calculated by comparing the human AGT protein levels of the siRNA group and the vehicle group. The knockdown effect of DAW30255 on AGT is shown in the attached figure. Figure 2 ). The experimental results show that the siRNA conjugate of the present invention can significantly reduce the expression of AGT. Therefore, the DAW30255 of the present invention has a good application prospect in the treatment of hypertension.
[0525] The above mouse experiments show that the GalNAc vector of the present invention has a good delivery effect on AGT and HBV target siRNA drugs. According to the common knowledge in the art, a specific embodiment of the present invention is a vector that delivers anti-hepatitis B drugs to treat hepatitis B, or AGT drugs to treat hypertension through liver-targeted delivery, which has a good delivery effect. Therefore, the vector of the present invention can also be used for the delivery of other liver-targeted drugs.
[0526] Although the present invention has been described in detail above by means of general description, specific implementation methods and tests, it is obvious to those skilled in the art that some modifications or improvements may be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A compound having a structure as shown in formula (I), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (I), in, Ring A is a heterocyclic group consisting of 3 to 12 atoms or a cycloalkyl group consisting of 3 to 12 atoms; Z and Y are each independently H, deuterium, a hydroxyl protecting group, HOC(=O)(CH2) j C(=O)- or MC(=O)(CH2) j C(=O)-; M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG; Each of L1, L2 and L3 is independently C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl, C 2-12 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-; R is a structure represented by the following formula (a) or formula (b): Among them, each X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H or a hydroxyl protecting group; each Y1, Y2, Y3, Y4, Y5 is independently H or an amino protecting group; Each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein each C 1-12 Alkylene, C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-; Each of B1, B2, B3, B4 and B5 is independently C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 ring atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl or C 2-12 Alkynyl, wherein at least one of B1 and B2 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, at least one of B3, B4 and B5 is C 3-12 Cycloalkyl or heterocyclic group consisting of 3-12 ring atoms, wherein each C 3-12 Cycloalkyl, heterocyclic group consisting of 3-12 atoms, C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-12 Alkylene, C 1-12 Heteroalkyl, C 2-12 Alkenyl and C 2-12 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )-; Each R 1 are independently H, deuterium or C 1-6 alkyl; wherein each j is independently 1, 2, 3, 4 or 5; Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxyl, nitro, cyano, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 2-6 Alkenyl or C 1-6 Heteroalkyl.
2. The compound according to claim 1, wherein Each of L1, L2 and L3 is independently C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, -O-, -S-, -S(=O)-, -S(=O)2-, -S(=O)(=NR 1 )-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- or -N(R 1 )-, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W1 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )- is replaced by a group.
3. The compound according to claim 1 or 2, wherein Each of A1, A2, A3, A4, A5, C1, C2, C3, C4 and C5 is independently a bond, C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl or C 2-10 Alkynyl, wherein each C 3-12 Alkylene, C 3-6 Cycloalkyl, heterocyclic group consisting of 3-6 ring atoms, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W2 Replace, each C 3-12 Alkylene, C 2-10 Heteroalkyl, C 2-10 Alkenyl and C 2-10 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )- is replaced by a group.
4. The compound according to any one of claims 1 to 3, wherein Each of B1, B2, B3, B4 and B5 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3 to 6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl or C 2-6 Alkynyl, wherein at least one of B1 and B2 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and at least one of B3, B4 and B5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or a heterocyclic group consisting of 3-6 ring atoms, and each of the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, a heterocyclic group consisting of 3-6 ring atoms, C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 Alkynyl is optionally substituted with 1, 2, 3 or 4 R W3 Replace, each C 1-6 Alkylene, C 1-6 Heteroalkyl, C 2-6 Alkenyl and C 2-6 1, 2, 3, 4 or 5 methylene groups in the alkynyl group are each independently optionally substituted by 1, 2, 3, 4 or 5 groups selected from -O-, -S-, -S(=O)-, -S(=O)2-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)C(=O)-, -C(=O)N(R 1 )-、-N(R 1 )C(=O)-、-OC(=O)N(R 1 )-、-N(R 1 )C(=O)O-、-N(R 1 )C(=O)N(R 1 )-、-C(=O)N(R 1 )C(=O)-、-S(=O)2N(R 1 )-、-N(R 1 )S(=O)2- and -N(R 1 )- is replaced by a group.
5. The compound according to any one of claims 1 to 4, wherein Z and Y are each independently H, deuterium, C 1-12 Alkyl, C 1-12 Alkyl C(=O)-, C 1-12 Alkyl methyl, C 1-12 Alkylsilyl, C 6-10 Aryl C 1-6 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; or Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-10 Alkyl, C 1-10 Alkyl C(=O)-, C 1-10 Alkyl methyl, C 1-10 Alkylsilyl, C 6-10 Aryl C 1-4 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; or Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-8 Alkyl, C 1-8 Alkyl C(=O)-, C 1-8 Alkyl methyl, C 1-8 Alkylsilyl, phenyl C 1-3 Alkyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; or Z and Y are each independently H, deuterium, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, p-methoxybenzyldiphenylmethyl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, C 1-6 Alkyl, C 1-6 Alkyl C(=O)-, C 1-6 Alkyl methyl, C 1-6 Alkylsilyl, benzyl, phenethyl, HOC(=O)(CH2) j C(=O)-、MC(=O)(CH2) j C(═O)-, triphenylmethyl, MMTr, DMTr or 4',4',4'-trimethoxytrityl; The ring A is a heterocyclic group consisting of 3-7 atoms or a cycloalkyl group consisting of 3-6 atoms, more preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl.
6. The compound according to any one of claims 1 to 5, wherein Each X1, X2, X3, X4, X5, X6, X7, X8, X9, 10 , X 11 , X 12 , X 13 , X 14 and X 15 are independently H, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, biphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, tert-butyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl, p-methoxybenzyldiphenylmethyl, trityl, tetrahydrofuranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-trichloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methylsulfonyl, p-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, C 1-6 Alkoxy or R 2 C(=O)-; Each of Y1, Y2, Y3, Y4 and Y5 is independently H, 9-fluorenylmethoxycarbonyl or R 3 C(=O)-; Among them, each R 2 and R 3 Independently for C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, phenyl, halogen-substituted phenyl, C 1-6 Alkylphenyl or benzyl; or Each R 2 and R 3 Independently for C 1-4 Alkyl, halogenated C 1-6 Alkyl, C 1-4 Alkoxy, phenyl, halogen-substituted phenyl, C 1-4 Alkylphenyl or benzyl; or Each R 2 and R 3 are independently methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, monofluoromethyl, trichloromethyl, dichloromethyl, monochloromethyl, 2,2,2-trichloroethyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, tert-butoxy, phenyl, halogen-substituted phenyl, C 1-3 Alkylphenyl or benzyl; Each R 1 are independently H, deuterium or C 1-4 alkyl; Each R W1 , R W2 and R W3 are independently deuterium, =O, hydroxy, nitro, cyano, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, 1-propoxy, 2-propoxy, 1-butoxy, 2-methyl-1-propoxy, 2-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C 2-4 Alkenyl or C 1-4 Heteroalkyl.
7. The compound according to any one of claims 1 to 6, wherein R is a structure represented by the following formula (a-1) or formula (b-1): Among them, each X1, X2, X3, X4, X5, X6, X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 The definitions of Y1, Y2, Y3, Y4, Y5, A1, A2, A3, A4, A5, B1, B2, B3, B4, B5, C1, C2, C3, C4 and C5 have the meanings as described in any one of claims 1-6.
8. A compound according to any one of claims 1 to 7, having a structure as shown in formula (II), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (II), in, The definitions of Z, Y, L1, L2, L3 and R have the meanings as described in any one of claims 1-6.
9. A compound according to any one of claims 1 to 8, having a structure as shown in formula (III), or a stereoisomer, tautomer or acceptable salt of the compound as shown in formula (III), in, Each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ; each of F1, F2 and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl; Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4; Among them, each R 1 , X7, X8, X9, X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , Y3, Y4, Y5, Z and Y have the meanings as described in any one of claims 1-6.
10. The compound according to any one of claims 1 to 9, which has one of the compounds shown below, or a stereoisomer, tautomer or acceptable salt thereof, M is a solid support, preferably a hydroxyl- or amino-functionalized solid support, more preferably a resin or CPG, further preferably a macroporous resin or CPG, and further preferably an aminomethyl resin, a hydroxyl resin or -NHCPG.
11. A conjugated group comprising a structure as shown in formula (Ia), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (Ia), in, R x It is a structure of formula (c) or formula (d): Each ring A, A1, A2, A3, A4, A5, B1, B2, B3, B 4、 The definitions of B5, C1, C2, C3, C4, C5, Y1, Y2, Y3, Y4, Y5, L1, L2 and L3 have the meanings as described in any one of claims 1-6.
12. The conjugated group according to claim 11, wherein R x It is a structure shown in the following formula (c-1) or formula (d-1): Among them, A1, A2, A3, A4, A5, B1, B2, B3, B 4、 The definitions of B5, C1, C2, C3, C4, C5, Y1, Y2, Y3, Y4 and Y5 have the meanings as described in any one of claims 1-6.
13. The conjugated group according to claim 11 or 12, which has a structure as shown in formula (II-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (II-a), Each R x The definitions of L1, L2 and L3 have the meanings as described in any one of claims 1-6.
14. The conjugated group according to any one of claims 11 to 13, which has a structure as shown in formula (III-a), or a stereoisomer, tautomer or acceptable salt of the structure as shown in formula (III-a), in, Each of D1, D2 and D3 is independently -C(=O)- * 、-C(=O)O- * 、-OC(=O)- * 、-C(=O)N(R 1 )- * 、-N(R 1 )C(=O)- * 、-C(=O)N(R 1 )CH2- * or -N(R 1 )C(=O)CH2- * ; Each of F1, F2 and F3 is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; Each of n1, n2, n3, m1, m2, m3 and m4 is independently 0, 1, 2, 3 or 4; Among them, each R 1 , Y3, Y4 and Y5 have the meanings as defined in any one of claims 1-6.
15. The conjugated group according to any one of claims 11 to 14, which has one of the structures shown below, or a stereoisomer, tautomer or acceptable salt thereof, 16 . A nucleic acid conjugate, comprising the conjugated group according to any one of claims 11 to 15 and a nucleic acid, wherein the nucleic acid is a modified or unmodified nucleic acid. The nucleic acid conjugate according to claim 16 , wherein the nucleic acid is linked to the conjugated group via a phosphate group, a phosphorothioate group or a phosphate group. The nucleic acid conjugate according to claim 16 or 17, wherein the conjugated group is conjugated to the 3' end or the 5' end of the nucleic acid.
19. The nucleic acid conjugate according to any one of claims 16 to 18, wherein the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid, preferably siRNA; optionally, the conjugated group is preferably conjugated to the 3' end or 5' end of the sense strand of the siRNA, more preferably to the 3' end of the sense strand of the siRNA.
20. An siRNA conjugate, which is one of DAW30223, DAW30062, DAW30219, DAW30221, DAW30222 and DAW30255, DAW30223: DAW30223: Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40002-4 (SEQ ID NO: 2) Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ IDNO: 7) DAW30062: Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40003-4 (SEQ ID NO: 3) Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ IDNO: 7) DAW30219: Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40004-4 (SEQ ID NO: 4) Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ IDNO: 7) DAW30221: Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40005-4 (SEQ ID NO: 5) Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ IDNO: 7) DAW30222: Sense strand (5'-3'): gs-us-gu-Gf-c-Af-Cf-Uf-ucgcuucaca-DAW40007-4 (SEQ ID NO: 6) Antisense strand (5'-3'): us-Gfs-uga-Agn-g-Cf-Gf-aagu-Gf-c-Af-ca-cs-us-u (SEQ IDNO: 7) DAW30255: Sense strand (5'-3'): gs-us-cauc-Cf-a-Cf-Af-Af-ugagaguaca-DAW40007-4 (SEQ ID NO: 8) Antisense strand (5'-3'): us-Gfs-uac-(Tgn)-cucauug-Uf-g-Gf-auga-cs-gs-a (SEQ ID NO: 9) in, The conjugate groups DAW40002-4, DAW40003-4, DAW40004-4, DAW40005-4 and DAW40007-4 are each conjugated to the 3' end of the siRNA sense strand via a phosphate group, and the structures thereof are shown below:
21. A pharmaceutical composition comprising the siRNA conjugate according to claim 20 and a pharmaceutically acceptable carrier.
22. Use of the compound of any one of claims 1 to 10, the conjugated group of any one of claims 11 to 15, or the nucleic acid conjugate of claims 16 to 19 in the preparation of a medicament for treating and / or preventing a pathological condition or disease caused by the expression of a specific gene in hepatocytes.
23. The use according to claim 22, wherein the specific gene is selected from ApoB, ApoC3, AGT, ANGPTL3, PCSK9, LPA, SCD1, FVII, p53, HBV or HCV.
24. Use of DAW30223, DAW30062, DAW30219, DAW30221 and / or DAW30222, or a combination thereof, in the preparation of a medicament for treating and / or preventing hepatitis B disease, or use of DAW30255 or a combination thereof in the preparation of a medicament for treating and / or preventing hypertension.
Citation Information
Cited By
Novel double-stranded sirna, conjugate thereof, and use thereof
WO2025130862A1
